VolitionRx Limited (VNRX) 10-K 15 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 08, 2023	Jun. 30, 2022
Cover [Abstract]
Entity Registrant Name	VOLITIONRX LIMITED
Entity Central Index Key	0000093314
Document Type	10-K
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		63,096,766
Entity Public Float			$ 73,353,231
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-36833
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	91-1949078
Entity Interactive Data Current	Yes
Icfr Auditor Attestation Flag	false
Entity Address Address Line 1	1489 West Warm Springs Road,
Entity Address Address Line 2	Suite 110
Entity Address City Or Town	Henderson
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89014
City Area Code	646
Local Phone Number	650–1351
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	VNRX
Security Exchange Name	NYSEAMER
Auditor Firm Id	3627
Auditor Name	Sadler, Gibb & Associates, LLC
Auditor Location	Draper, UT

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 10,867,050	$ 20,581,313
Accounts Receivable	72,609	12,510
Prepaid expenses	784,920	598,367
Other current assets	447,566	786,642
Total Current Assets	12,172,145	21,978,832
Property and equipment, net	5,393,012	4,911,077
Operating lease right-of-use assets	619,392	383,551
Intangible assets, net	110,505	216,876
Total Assets	18,295,054	27,490,336
Current Liabilities
Accounts payable	3,043,008	1,542,457
Accrued liabilities	2,872,247	3,828,501
Deferred revenue	10,000,000	12,512
Management and directors' fees payable	71,119	71,303
Current portion of long-term debt	1,066,700	797,855
Current portion of financing lease liabilities	46,014	48,958
Current portion of operating lease liabilities	245,163	171,166
Current portion of grant repayable	41,836	43,100
Total Current Liabilities	17,386,087	6,515,852
Long-term debt, net of current portion	2,779,240	2,270,767
Finance lease liabilities, net of current portion	436,132	511,086
Operating lease liabilities, net of current portion	400,091	217,305
Grant repayable, net of current portion	420,466	253,221
Total Liabilities	21,422,016	9,768,231
Common Stock
Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 57,873,379 shares and 53,772,261 shares, respectively	57,873	53,772
Additional paid-in capital	164,397,468	154,730,938
Accumulated other comprehensive income	227,097	148,326
Accumulated deficit	(167,257,429)	(136,988,636)
Total VolitionRx Limited Stockholders' Equity (Deficit)	(2,574,991)	17,944,400
Non-controlling interest	(551,971)	(222,295)
Total Stockholders' Equity (Deficit)	(3,126,962)	17,722,105
Total Liabilities and Stockholders' Equity	$ 18,295,054	$ 27,490,336

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Consolidated Balance Sheets
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares Par Value	$ 0.001	$ 0.001
Common Stock, Shares Issued	57,873,379	53,772,261
Common Stock, Shares Outstanding	57,873,379	53,772,261

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues
Royalty	$ 2,911	$ 0
Service	92,488	0
Product	210,993	90,035
Total Revenues	306,392	90,035
Operating Expenses
Research and development	14,572,532	13,022,411
General and administrative	10,937,686	11,676,446
Sales and marketing	6,576,246	3,724,257
Total Operating Expenses	32,086,464	28,423,114
Operating Loss	(31,780,072)	(28,333,079)
Other Income (Expenses)
Grant income	1,229,425	1,522,533
Loss on disposal of fixed assets	0	(26,166)
Interest income	125,265	2,734
Interest expense	(173,087)	(155,803)
Total Other Income	1,181,603	1,343,298
Net Loss	(30,598,469)	(26,989,781)
Net Loss attributable to Non-Controlling Interest	329,676	175,116
Net Loss attributable to VolitionRx Limited Stockholders	(30,268,793)	(26,814,665)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	78,771	208,304
Net Comprehensive Loss	$ (30,519,698)	$ (26,781,477)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited Stockholders	$ (0.55)	$ (0.51)
Weighted Average Shares Outstanding
- Basic and Diluted	55,350,401	52,655,885

Consolidated Statement of Stock

Consolidated Statement of Stockholders Equity (Deficit) - USD ($)	Total	Common stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)	Noncontrolling Interest
Balance, shares at Dec. 31, 2020		48,607,017
Balance, amount at Dec. 31, 2020	$ 16,293,718	$ 48,607	$ 126,526,239	$ (59,978)	$ (110,173,971)	$ (47,179)
Common stock issued for cashless exercise of stock options, shares		77,451
Common stock issued for cashless exercise of stock options, amount	0	$ 77	(77)	0	0	0
Common stock issued for settlement of RSUs, shares		24,712
Common stock issued for settlement of RSUs, amount	0	$ 25	(25)	0	0	0
Common stock issued in public offerings, net, shares		5,063,081
Common stock issued in public offerings, net, amount	23,219,644	$ 5,063	23,214,581	0	0	0
Tax withholdings paid related to stock-based compensation	(130,426)	0	(130,426)	0	0	0
Stock-based compensation	2,670,297	0	2,670,297	0	0	0
Stock-based compensation in relation to modification of options	2,450,349	0	2,450,349	0	0	0
Foreign currency translation	208,304	0	0	208,304	0	0
Net loss for the Year	(26,989,781)	$ 0	0	0	(26,814,665)	(175,116)
Balance, shares at Dec. 31, 2021		53,772,261
Balance, amount at Dec. 31, 2021	17,722,105	$ 53,772	154,730,938	148,326	(136,988,636)	(222,295)
Common stock issued for settlement of RSUs, shares		297,289
Common stock issued for settlement of RSUs, amount	0	$ 297	(297)	0	0	0
Common stock issued in public offerings, net, shares		3,803,829
Common stock issued in public offerings, net, amount	6,736,444	$ 3,804	6,732,640	0	0	0
Tax withholdings paid related to stock-based compensation	(180,472)	0	(180,472)	0	0	0
Stock-based compensation	3,114,659	0	3,114,659	0	0	0
Foreign currency translation	78,771	0	0	78,771	0	0
Net loss for the Year	(30,598,469)	$ 0	0	0	(30,268,793)	(329,676)
Balance, shares at Dec. 31, 2022		57,873,379
Balance, amount at Dec. 31, 2022	$ (3,126,962)	$ 57,873	$ 164,397,468	$ 227,097	$ (167,257,429)	$ (551,971)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Activities:
Net loss	$ (30,598,469)	$ (26,989,781)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	936,084	945,367
Amortization of operating lease right-of-use assets	253,864	199,793
Loss on disposal of fixed assets	0	26,166
Stock based compensation	3,114,659	2,670,297
Stock-based compensation in relation to modification of options	0	2,450,349
Changes in operating assets and liabilities:
Prepaid expenses	433,995	(295,189)
Accounts receivable	(72,609)	(12,510)
Other current assets	351,514	(202,801)
Deferred revenue	9,987,488	12,512
Accounts payable and accrued liabilities	548,611	522,220
Management and directors' fees payable	(184)	16,129
Operating lease liabilities	(232,695)	(196,471)
Net Cash Used In Operating Activities	(15,277,742)	(20,853,919)
Investing Activities:
Purchases of property and equipment	(1,570,182)	(973,559)
Net Cash Used In Investing Activities	(1,570,182)	(973,559)
Financing Activities:
Net proceeds from issuance of common shares	6,736,444	23,219,644
Tax withholdings paid related to stock-based compensation	(180,472)	(130,426)
Proceeds from grants repayable	218,445	37,631
Proceeds from long-term debt	1,523,098	592,423
Payments on long-term debt	(1,268,386)	(755,721)
Payments on grants repayable	(45,664)	(47,789)
Payments on financing leases	(45,433)	(58,210)
Net Cash Provided By Financing Activities	6,938,032	22,857,552
Effect of foreign exchange on cash and cash equivalents	195,629	106,502
Net Change in Cash and Cash Equivalents	(9,714,263)	1,136,576
Cash and Cash Equivalents - Beginning of Year	20,581,313	19,444,737
Cash and Cash Equivalents - End of Year	10,867,050	20,581,313
Supplemental Disclosures of Cash Flow Information:
Interest paid	173,087	155,803
Income tax paid	$ 0	$ 0
Non-Cash Financing Activities:
Common Stock issued on exercises of stock options and warrants and settlement of RSUs	297	102
Offering costs from issuance of common stock	$ 427,443	$ 218,459
Non-cash Note Payable	$ 620,549	$ 0

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2022
Nature of Operations
Nature of Operations	Note 1 - Nature of Operations The Company was incorporated under the laws of the State of Delaware on September 24, 1998. On September 22, 2011, the Company filed a Certificate for Renewal and Revival of Charter with the Secretary of State of Delaware. Pursuant to Section 312(1) of the Delaware General Corporation Law, the Company was revived under the new name of “VolitionRX Limited” and the name change became effective on October 11, 2011. On October 7, 2016, the Company amended its Certificate of Incorporation to reflect a name change to “VolitionRx Limited.” On October 6, 2011, the Company entered into a share exchange agreement with Singapore Volition Pte. Limited, a Singapore corporation incorporated on August 5, 2010 (“Singapore Volition”), and the shareholders of Singapore Volition. Pursuant to the terms of the share exchange agreement, the former shareholders of Singapore Volition held 85% of the issued and outstanding common shares of the Company. The issuance was deemed to be a reverse acquisition for accounting purposes and as such, Singapore Volition is regarded as the predecessor of the Company. The number of shares outstanding and per share amounts of the Company have been restated to recognize the foregoing recapitalization. The Company’s principal business objective through its subsidiaries is to develop and bring to market simple, easy to use, cost effective blood tests designed to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics TM

Liquidity and Going Concern Ass

Liquidity and Going Concern Assessment	12 Months Ended
	Dec. 31, 2022
Liquidity and Going Concern Assessment
Liquidity and Going Concern Assessment	No te 2 – Liquidity and Go ing Concern Assessment The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America (“U.S. GAAP”), applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of $167.3 million, has negative cash flows from operations, and has minimal revenues, which creates substantial doubt about its ability to continue as a going concern for a period at least one year from the date of issuance of these consolidated financial statements. The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by, (a) securing additional grant funds, (b) obtaining additional financing through debt or equity transactions; (c) granting licenses and/or distribution rights to third parties in exchange for specified up-front and/or back-end payments, and (d) developing and commercializing its products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and to eventually attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3 - Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP and are expressed in US dollars. The Company’s fiscal year end is December 31. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets and valuations of stock-based compensation. The Company bases its estimates and assumptions on current facts, historical experiences and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected. Principles of Consolidation The accompanying consolidated financial statements for the year ended December 31, 2022 include the accounts of the Company and its subsidiaries. The Company has two wholly owned subsidiaries, Singapore Volition Pte. Limited and Volition Global Services SRL. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL. Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited, Volition America, Inc, Volition Germany GmbH, and its one majority owned subsidiary Volition Veterinary Diagnostics Development LLC. See Note 10 (f), Commitments and Contingencies – Other Commitments Reclassification Certain amounts presented in previously issued financial statements have been reclassified to be consistent with the current period presentation. In the statement of operations and comprehensive loss, the Company has reclassified the prior year comparative amounts of research and development, sales and marketing and general and administrative expenses to be consistent with the current year classification. Cash and Cash Equivalents The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,867,050 and $20,581,313, respectively, in cash and cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,079,089 and $19,753,878, respectively, in its domestic accounts in excess of Federal Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $1,725,981 and $134,134, respectively, in its foreign accounts in excess of the Belgian Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $100,601 and $102,514, respectively, in its foreign accounts in excess of the Singapore Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $326,631 and $142,410, respectively, in its foreign accounts in excess of the UK Deposit insured limits. Accounts Receivable Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of December 31, 2022, the accounts receivable balance was $72,609 and the allowance for doubtful accounts was $nil. Property and Equipment Property and equipment are stated at historical cost and depreciated over the useful life of the asset using the straight-line method. Useful lives are assigned to assets depending on their category. For details regarding property and equipment, refer to Note 4. Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with Accounting Standards Codification (“ASC”) 260, “Earnings Per Share,” Foreign Currency Translation The Company has functional currencies in Euros, US Dollars and British Pounds Sterling and its reporting currency is the US Dollar. Management has adopted ASC 830-20, “Foreign Currency Matters – Foreign Currency Transactions” Fair Value Measurements Pursuant to ASC 820, “ Fair Value Measurements and Disclosures,” Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable, accrued liabilities, notes payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consists of quoted prices in active markets for identical assets. The Company believes that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. Other Comprehensive Income (Loss) ASC 220, “ Other Comprehensive Income/(Loss)”, Income Taxes Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740, “Accounting for Income Taxes” Revenue Recognition The Company adopted ASC 606, “ Revenue from Contracts with Customers,” The Company generates product revenues from the sale of its Nu.Q ® Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows: Royalty The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented under “Royalty” under the consolidated statements of operations. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known. Product The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in “Product” in the consolidated statements of operations and comprehensive loss. Service The Company includes revenue recognized from laboratory services performed in the Company’s laboratory on behalf of third parties under “Service” under the consolidated statements of operations. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. Licensing The Company includes revenue recognized from the licensing of certain rights to third parties in “Licensing” in the consolidated statements of operations and comprehensive loss. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. Revenue from Heska License Agreement On March 28, 2022, Belgian Volition entered into a Master License and Supply Agreement (the “License Agreement”) with Heska Corporation (“Heska”), pursuant to which Belgian Volition granted Heska worldwide exclusive rights to sell the Nu.Q® Vet Cancer Test at the point of care (“POC”) initially for the screening of lymphoma and hemangiosarcoma in dogs (“Canine Lymphoma & HSA”), and non-exclusive rights to sell its Nu.Q® Vet Cancer Test in kit format (“Kits”) through Heska’s network of central reference laboratories (“Central Lab”) initially for Canine Lymphoma & HSA. Under and subject to the terms of the License Agreement, Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines. The License Agreement contains additional time-based triggers for the payment of the above-described milestones as well. Any further expansion of the License Agreement to cover other cancer and non-cancer indications is subject to negotiation between the parties. Belgian Volition will also supply Central Lab Kits and will receive a pre-agreed price per test, adjusted annually for inflation. The price per test for POC key components (“Key Components”) is also discounted to reflect the lower cost to Belgian Volition and additional assembly costs for Heska, as well as consideration for Heska’s upfront and milestone payments. Heska will assemble the Key Components for use at the POC, and is additionally responsible for marketing and distribution efforts and related costs. The License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party’s insolvency. Heska also has the option to terminate if it is unable to adapt the Key Components for use on a POC platform. Unless earlier terminated, the License Agreement will continue in effect for an initial term of 22 years for POC and 5 years for Central Lab, with the Central Lab term then continuing on a rolling one-year basis for the POC term. According to ASC Topic 606, “ Revenue from Contracts with Customers In conjunction with the License Agreement, the Company evaluated whether or not the performance obligations granted under the License Agreement were distinct and concluded that they were not distinct as Heska could not benefit from the license without the supply (manufacturing) services. The supply services are highly specialized and are dependent on the supply of the product from the Company. As such, the performance obligations granted under the License Agreement were combined to constitute a single performance obligation and the Company accounts for them as a single contract. During the first quarter of 2022, the Company received a $10.0 million upfront payment under the License Agreement, which is included as deferred revenue on the accompanying consolidated balance sheet as of December 31, 2022. The Company allocated the upfront payment and any milestone payments that were not constrained to the single performance obligation in the contract. The Company expects to recognize the $10.0 million upfront payment and any milestone amounts not constrained under the License Agreement over time using an output method based on Key Components and Kits supplied to Heska. As of December 31, 2022, the remaining $18.0 million in milestone payments under the License Agreement remains constrained and will not begin to be recognized until such amount becomes unconstrained. In determining the transaction price, the Company analyzed the variable consideration and whether or not such variable consideration was constrained. The Company will reassess this variable consideration at each reporting period and adjust the transaction price, if necessary. The total Key Components and Kits that the Company expects to manufacture for Heska over the life of the contract will be a significant judgment in recognizing revenue once the Company begins to supply product to Heska. Deferred Revenue (Contract Liabilities) and Contract Assets Deferred revenue consists of amounts for which the Company has an unconditional right to bill, and/or amounts for which payment has been received (including non-refundable amounts) but have not been recognized as revenue because the related performance obligations are deemed incomplete. As of December 31, 2022, the Company recorded $10.0 million as deferred revenue in respect of a non-refundable payment received in relation to a licensing and product supply agreement with Heska Corporation. As of December 31, 2021, the Company recorded $12,512 as deferred revenue. Contract assets include costs and services incurred on contracts with open performance obligations. These contract assets were immaterial as of December 31, 2022. Research and Development In accordance with ASC 730, the Company follows the policy of expensing its research and development costs in the period in which they are incurred. The Company incurred research and development expenses of $14.6 million and $13.0 million during the years ended December 31, 2022 and 2021, respectively. Impairment of Long-Lived Assets In accordance with ASC 360, “Property Plant and Equipment”, Stock-Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Compensation – Stock Compensation” Leases The Company accounts for leases in accordance with ASC Topic 842, “Leases.” The Company determines whether a contract is a lease at contract inception or for a modified contract at the modification date. At inception or modification, the Company recognizes right-of-use assets (“ROU”) and related lease liabilities on the balance sheet for all leases greater than one year in duration. Lease liabilities and their corresponding ROU assets are initially measured at the present value of the unpaid lease payments as of the lease commencement date. If the lease contains a renewal and/or termination option, the exercise of the option is included in the term of the lease if the Company is reasonably certain that a renewal or termination option will be exercised. As the Company’s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate (“IBR”) based on the information available at the commencement date of the respective lease to determine the present value of future payments. The IBR is determined by estimating what it would cost the Company to borrow a collateralized amount equal to the total lease payments over the lease term based on the contractual terms of the lease and the location of the leased asset. Operating lease payments are recognized as an expense on a straight-line basis over the lease term in equal amounts of rent expense attributed to each period during the term of the lease, regardless of when actual payments are made. This generally results in rent expense in excess of cash payments during the early years of a lease and rent expense less than cash payments in later years. The difference between rent expense recognized and actual rental payments is typically represented as the spread between the ROU asset and lease liability. When calculating the present value of minimum lease payments, we account for leases as one single lease component if a lease has both lease and non-lease fixed cost components. Variable lease and non-lease cost components are expensed as incurred. We do not recognize ROU assets and lease liabilities for short-term leases that have an initial lease term of 12 months or less. We recognize the lease payments associated with short-term leases as an expense on a straight-line basis over the lease term. Grant Income The Company receives funding from public bodies for a proportion of the costs of specific projects. Funds are received in line with claims submitted for the agreed expenditure. The Company recognizes grant income once claims submitted are approved and funds are received. General working capital funding received at the commencement of a project is treated as deferred income and is recorded in accrued liabilities until it has been utilized for the expenditure claimed. Funding received that is repayable is shown as a liability. The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. COVID-19 Pandemic Impact As of the date of this filing, there continue to be widespread concerns regarding the ongoing impacts and disruptions caused by the COVID-19 pandemic in the regions in which the Company operates. As a result of the impacts of the COVID-19 pandemic, the Company has experienced and may continue to experience disruptions to its clinical trials, including patient enrollment and sample collection delays. Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic, the extent to which the pandemic will impact its business, financial condition, and results of operations in future periods is highly uncertain and will be affected by a number of factors outside of the Company’s control. These include the duration and extent of the COVID-19 pandemic, the development of new variants of the COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and mitigation measures, the effect of government stabilization and recovery efforts, and the success of vaccine distribution programs. Recent Accounting Pronouncements In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU amends ASC 805 to require acquiring entities to apply ASC 606 to recognize and measure contract assets and contract liabilities in business combinations. The standard is effective for the Company's fiscal year beginning January 1, 2023, with early adoption permitted. The adoption of this standard is not expected to have a material effect on our financial position, results of operations, or cash flows.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2022
Property and Equipment
Property And Equipment	Note 4 - Property and Equipment The Company’s property and equipment consist of the following amounts as of December 31, 2022 and December 31, 2021: December 31, 2022 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 656,759 497,306 159,453 Laboratory equipment 5 years 4,190,289 1,951,387 2,238,902 Office furniture and equipment 5 years 358,575 239,436 119,139 Buildings 30 years 2,054,332 298,397 1,755,935 Building improvements 5-15 years 1,317,132 326,337 990,795 Land Not amortized 128,788 - 128,788 8,705,875 3,312,863 5,393,012 December 31, 2021 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 599,944 474,169 125,775 Laboratory equipment 5 years 3,032,108 1,434,347 1,597,761 Office furniture and equipment 5 years 293,427 213,244 80,183 Buildings 30 years 2,177,641 243,750 1,933,891 Building improvements 5-15 years 1,293,258 256,309 1,036,949 Land Not amortized 136,518 - 136,518 7,532,896 2,621,819 4,911,077 During the years ended December 31, 2022 and December 31, 2021, the total capital expenditure was $1.6 million and $1.1 million, respectively, the majority of which was from purchases of laboratory equipment. For further details refer to Note 10 (a) for Finance Leases included in Property, Plant and Equipment. During the years ended December 31, 2022 and December 31, 2021, the Company recognized $865,262 and $812,109, respectively, in depreciation expense.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2022
Intangible Assets
Intangible Assets	Note 5 - Intangible Assets The Company’s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assets’ estimated useful lives, which range from 8 to 20 years. December 31, 2022 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,104,103 993,598 110,505 December 31, 2021 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,178,135 961,259 216,876 During the years ended December 31, 2022 and December 31, 2021, the Company recognized $75,558 and $91,645, respectively, in amortization expense. The Company amortizes the long-lived assets on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows: Remaining Remaining Life Amortization 2023 $ 85,636 2024 $ 24,869 Total Intangible Assets $ 110,505 The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2022. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, 2022.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions
Related Party Transactions	Note 6 - Related Party Transactions See Note 7 for common stock issued to related parties and Note 8 for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of products and consultancy services which are accrued under accruals and management and directors’ fees payable (see consolidated balance sheets).

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2022
Common Stock
Common Stock	Note 7 - Common Stock As of December 31, 2022, the Company was authorized to issue 100 million shares of common stock par value $0.001 per share, of which 57,873,379 and 53,772,261 shares were issued as of December 31, 2022 and December 31, 2021, respectively. 2022 Stock Option Exercises During the year ended December 31, 2022 no shares of common stock were issued pursuant to the exercise of stock options. 2021 Stock Option Exercises During the year ended December 31, 2021 we issued a total of 77,451 shares of common stock from the cashless exercise of options, as follows: Date Stock Incentive Plan Stock Options Price Per Share Shares Issued # $ # January 13 - March 19, 2021 2011 7,634 3.35 948 February 2, 2021 2011 20,000 3.80 6,181 February 8, 2021 2011 15,000 4.00 5,769 February 8, 2021 2015 100,000 5.00 19,446 February 8 - February 9, 2021 2015 85,000 4.00 26,357 February 8, 2021 2015 50,000 3.25 18,750 277,634 77,451 RSU Settlements 2022 During the year ended December 31, 2022 we issued a total of 297,289 shares of common stock from the settlement of RSUs, as follows: Date Restricted Stock Units Vested Price Settled Per Share Shares Issued Shares Withheld for Tax # $ # # March 25, 2022 15,000 3.01 15,000 - April 13, 2022 26,250 2.95 21,712 4,538 May 1, 2022 50,000 2.79 35,000 15,000 August 3, 2022 230,102 1.97 191,992 38,110 September 7, 2022 12,000 1.65 7,038 4,962 October 4, 2022 19,905 1.46 13,022 6,883 November 1, 2022 21,750 1.97 12,344 9,406 December 15, 2022 2,000 1.97 1,181 819 377,007 297,289 79,718 2021 During the year ended December 31, 2021 we issued a total of 24,712 shares of common stock from the settlement of RSUs, as follows: Date Restricted Stock Units Vested Price Settled Per Share Shares Issued Shares Withheld for Tax # $ # # January 20, 2021 5,000 4.10 3,000 2,000 April 21, 2021 26,250 3.44 21,712 4,538 31,250 24,712 6,538 Equity Capital Raises 2022 On July 29, 2022, the Company entered into an underwriting agreement with Newbridge Securities Corporation (“Newbridge”) in connection with an underwritten public offering of 3,450,000 shares of the Company’s common stock, which includes Newbridge’s exercise in full of its overallotment option (of 450,000 shares), pursuant to the Company’s “shelf” registration statement on Form S-3 (declared effective by the SEC on November 8, 2021, File No. 333-259783) (as amended and supplemented from time to time, the “2021 Form S-3”). Newbridge purchased the shares from the Company at a weighted average price of $1.87 per share. The offering closed on August 2, 2022. The Company received net proceeds of approximately $6.4 million from the offering before deducting offering expenses of $0.2 million paid by the Company. Equity Capital Raises 2021 On February 10, 2021, the Company entered into an underwriting agreement with Cantor Fitzgerald & Co. (“Cantor”) in connection with an underwritten public offering of 3,809,524 shares of the Company’s common stock, pursuant to the Company’s “shelf” registration statement on Form S-3 (declared effective by the SEC on September 28, 2018, File No. 333-227248) (the “2018 Form S-3”). Cantor purchased the shares from the Company at a price of $4.9533 per share, and elected not to exercise an option to purchase up to an additional 571,428 shares of common stock at the same price per share. The offering closed on February 12, 2021. The Company received net proceeds of approximately $18.9 million from the offering before deducting offering expenses. Equity Distribution Agreements 2022 On May 20, 2022, the Company entered into an equity distribution agreement (the “2022 EDA”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an “at the market” offering pursuant to the Company’s 2021 Form S-3 through Jefferies acting as the Company’s agent and/or principal. The Company is not obligated to sell any shares under the 2022 EDA. As of December 31, 2022, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $0.8 million under the 2022 EDA through the sale of 350,829 shares of common stock, before deducting offering expenses. See Note 11 for additional details regarding the Company’s equity distribution agreements subsequent to December 31, 2022. From January 1, 2022 through May 7, 2022, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $9,500 under the 2021 EDA (as defined below) through the sale of 3,000 shares of its common stock. The Company terminated the 2021 EDA effective May 7, 2022. 2021 On September 24, 2021, the Company entered into an equity distribution agreement (the “2021 EDA”) with Cantor and Oppenheimer & Co. Inc. (“Oppenheimer”) to sell shares of the Company’s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an “at the market” offering pursuant to the Company’s 2021 Form S-3 through Cantor and Oppenheimer acting as the Company’s agents and/or principals. From the 2021 EDA’s effectiveness on November 8, 2021 through December 31, 2021, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $0.7 million through the sale of 190,600 shares of its common stock. On November 10, 2020, the Company entered into an equity distribution agreement (the “2020 EDA”) with Cantor and Oppenheimer to sell shares of the Company’s common stock, with an aggregate offering price of up to $25.0 million, from time to time through an “at the market” offering pursuant to the 2018 Form S-3 through Cantor and Oppenheimer acting as the Company’s agents and/or principals. During the year ended December 31, 2021 (and from inception of the 2020 EDA), the Company raised aggregate net proceeds (net of broker commissions and fees) of $2.7 million under the 2020 EDA through the sale of 754,348 shares of its common stock. The Company terminated the 2020 EDA effective November 8, 2021. On September 7, 2018, the Company entered into an equity distribution agreement (as amended, the “2018 EDA”) with Oppenheimer to sell shares of the Company’s common stock, with an aggregate offering price of up to $10.0 million, from time to time through an “at the market” offering pursuant to the 2018 Form S-3 through Oppenheimer acting as the Company’s agent and/or principal. The Company utilized the 2018 EDA in full during the three months ended March 31, 2021, and raised aggregate net proceeds (net of broker commissions and fees) of approximately $9.7 million under the 2018 EDA since inception through the sale of 2,539,606 shares of its common stock. During the year ended December 31, 2021, the Company raised aggregate net proceeds (net of broker commissions and fees) of $1.2 million under the 2018 EDA through the sale of 308,609 shares of its common stock. 2022 and 2021 Issuances Upon Warrant Exercises For the years ended December 31, 2022 and December 31, 2021 no warrants were exercised.

StockBased Compensation

StockBased Compensation	12 Months Ended
	Dec. 31, 2022
StockBased Compensation
Stock-based Compensation	No te 8 - Stock-Based Compensation a ) Warrants The following table summarizes the changes in warrants outstanding of the Company during the year ended December 31, 2022 and December 31, 2021: Weighted Average Number of Exercise Price Warrants $ Outstanding at December 31, 2020 175,000 2.75 Granted 310,000 4.52 Exercised - - Expired - - Outstanding at December 31, 2021 485,000 3.88 Granted 54,000 3.05 Exercised - - Expired - - Outstanding at December 31, 2022 539,000 3.80 Exercisable at December 31, 2022 485,000 3.88 2022 Effective April 4, 2022, the Company granted a warrant to purchase 54,000 shares of common stock to a Company employee for services to the Company and/or its subsidiaries. This warrant shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service and expire on April 4, 2028 and April 4, 2029, respectively, with an exercise price of $3.05 per share. The Company has calculated the estimated fair market value of this warrant at $80,901, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $2.95, exercise price $3.05, 71.07% volatility, 2.53% risk-free rate, and no forfeiture rate. 2021 Effective January 1, 2021, the Company granted warrants to purchase 125,000 shares of common stock to a Company employee for services to the Company. These warrants vest on January 1, 2022 (subject to continued employment through such date) and expire on January 1, 2027, with an exercise price of $3.95 per share. The Company has calculated the estimated fair market value of these warrants at $242,877, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $3.80, exercise price $3.95, 74.53% volatility, 0.50% risk free rate, and no forfeiture rate. Effective February 1, 2021, the Company granted warrants to purchase 185,000 shares of common stock to a Company employee for services to the Company. These warrants vested on February 1, 2022 (subject to continued employment through such date) and expire on February 1, 2027, with an exercise price of $4.90 per share. The Company has calculated the estimated fair market value of these warrants at $459,352, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $4.80, exercise price $4.90, 75.03% volatility, 0.59% risk free rate, and no forfeiture rate. Below is a table summarizing the warrants issued and outstanding as of December 31, 2022. The warrants outstanding have a weighted average price of $3.80 per share and an aggregate weighted average remaining contractual life of 3.24 years. The warrants exercisable have a weighted average price of $3.88 per share. Weighted Average Proceeds to Exercise Remaining Company if Number Number Price Contractual Exercised Outstanding Exercisable ($) Life (Years) $ 125,000 125,000 2.47 0.15 308,750 54,000 - 3.05 5.76 164,700 50,000 50,000 3.45 3.17 172,500 125,000 125,000 3.95 4.01 493,750 185,000 185,000 4.90 4.09 906,500 539,000 485,000 2,046,200 Stock-based compensation expense related to warrants of $84,102 and $701,781 was recorded for the years ended December 31, 2022, and December 31, 2021, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is approximately $35,812 and is expected to be recognized over a period of 1.26 years. As of December 31, 2022, the total intrinsic value of warrants was $0. b) Options The Company currently has options outstanding under both its 2011 Equity Incentive Plan (the “2011 Plan”) (for option issuances prior to 2016,) and its 2015 Stock Incentive Plan (the “2015 Plan”) (for option issuances commencing in 2016). Effective as of January 1, 2016, no additional awards were or may be made under the 2011 Plan. The 2015 Plan was adopted by the Board of Directors on August 18, 2015 and approved by the stockholders at an annual meeting held on October 30, 2015. On August 5, 2016, the Board of Directors adopted an amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 750,000 shares to an aggregate maximum of 1,750,000 shares, which amendment was approved by the stockholders at an annual meeting held on October 7, 2016. On June 13, 2017, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 750,000 shares to an aggregate maximum of 2,500,000 shares, which amendment was approved by the stockholders at an annual meeting held on September 8, 2017. On June 15, 2018, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 750,000 shares to an aggregate maximum of 3,250,000 shares, which amendment was approved by the stockholders at an annual meeting held on September 7, 2018. On March 27, 2019, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 1,000,000 shares to an aggregate maximum of 4,250,000 shares, which amendment was approved by the stockholders at an annual meeting held on June 14, 2019. On March 31, 2021, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such Plan by 1,750,000 shares to an aggregate maximum of 6,000,000 shares, which amendment was approved by the stockholders at an annual meeting held on June 17, 2021. On April 4, 2022, the Board of Directors adopted a subsequent amendment to the 2015 Plan to increase the number of shares of common stock available for issuance under such plan by 1,750,000 shares to an aggregate maximum of 7,750,000 shares, which amendment was approved by the stockholders at an annual meeting held on June 13, 2022. The 2015 Plan permits the grant of incentive stock options, non-statutory stock options, restricted stock awards, stock bonus awards, stock appreciation rights, restricted stock units and performance awards. The primary purpose of the 2015 Plan is to enhance the Company’s ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of the Company’s business largely depends, and to provide additional incentives to such persons or entities to devote their utmost effort and skill to the advancement and betterment of the Company, by providing them an opportunity to participate in the ownership of the Company that is tied to the Company’s performance, thereby giving them an interest in the success and increased value of the Company. The 2015 Plan is administered by the Compensation Committee comprised solely of members of the Board of Directors or by the Board of Directors as a whole. The following table summarizes the changes in options outstanding of the Company during the years ended December 31, 2022 and December 31, 2021: Weighted Average Number of Exercise Price Options $ Outstanding at December 31, 2020 4,278,619 4.00 Granted 1,090,000 3.41 Exercised (277,634 ) 4.19 Expired/Cancelled (63,467 ) 3.64 Outstanding at December 31, 2021 5,027,518 3.87 Granted - - Exercised - - Expired/Cancelled (42,413 ) 3.43 Outstanding at December 31, 2022 4,985,105 3.87 Exercisable at December 31, 2022 4,495,011 3.93 2022 During the year ended December 31, 2022, no options were granted. On August 18, 2022, 2,515 Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon the resignation of such employee. On November 18, 2022, 5,000 Options previously granted to an employee on April 13, 2020 were cancelled and returned as authorized shares under the 2015 Plan upon three months following the termination of such employee. On November 18, 2022, 32,383 Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon the resignation of such employee. On November 18, 2022, 2,515 Options previously granted to an employee on August 3, 2021 were cancelled and returned as authorized shares under the 2015 Plan upon three months following the termination of such employee. 2021 Effective May 20, 2021, the Company granted stock options to purchase 40,000 shares of common stock to a Company employee in exchange for services provided to the Company. These options vested on May 20, 2022 and were initially scheduled to expire six years after the grant date, with an exercise price of $3.60 per share. The Company extended the expiration date to ten years after the original grant date. The Company has calculated the estimated fair market value of these options at $73,641, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $3.50, exercise price $3.60, 76.16% volatility, 0.58% risk free rate, and no forfeiture rate. During the year ended December 31, 2021, the Company modified a total of 3,342,518 options to extend their expiration dates to ten years from the original dates of grant. This resulted in $2,450,349 of expense. The following table summarizes the amendments to the expiration dates of various options approved during the year ended December 31, 2021. Except as otherwise noted, the expiration dates for all options in the table below were extended from six years to ten years from the original date of grant. Amendment Equity Incentive Stock Options Grant New Expiration Option Expense Note Date Plan # Date Date $ (i) Jul 14, 2021 2011 292,000 Jul 23, 2015 Jul 23, 2025 442,273 Jul 14, 2021 2011 6,367 Mar 20, 2013 Mar 20, 2023 4,151 Jul 14, 2021 2011 8,151 Sep 2, 2013 Sep 2, 2023 6,009 Sep 21, 2021 2015 335,000 Apr 13, 2020 Apr 13, 2030 163,945 (ii) Sep 21, 2021 2015 89,163 Jan 23, 2018 Jan 23, 2028 24,194 (ii) Sep 21, 2021 2015 308,066 Feb 13, 2017 Feb 13, 2027 127,719 Nov 3, 2021 2015 760,000 Apr 15, 2016 Apr 15, 2026 984,511 Nov 3, 2021 2015 15,000 Jun 23, 2016 Jun 23, 2026 19,582 Nov 3, 2021 2015 50,000 Jan 1, 2017 Jan 1, 2027 32,456 Nov 3, 2021 2015 387,934 Mar 30, 2017 Mar 30, 2027 224,901 Nov 3, 2021 2015 615,837 Jan 23, 2018 Jan 23, 2028 213,646 Dec 8, 2021 2015 425,000 Apr 13, 2020 Apr 13, 2030 180,267 Dec 8, 2021 2015 10,000 Dec 1, 2020 Dec 1, 2030 5,209 Dec 8, 2021 2015 40,000 May 20, 2021 May 20, 2031 21,486 3,342,518 2,450,349 (i) The expiration date of these options were extended from five and a half years to ten years from the original date of grant. (ii) These options were previously amended on December 16, 2019 and amended again on September 21, 2021. Effective September 7, 2021, the Company granted stock options to purchase 50,000 shares of common stock to two employees in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with 25,000 shares vesting on September 7, 2022, and 25,000 shares vesting on September 7, 2023 subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The Company has calculated the estimated fair market value of these options at $98,322, using the Black-Scholes model and the following assumptions: term 5.5 years, stock price $3.32, exercise price $3.40, 68.98% volatility, 1.38% risk free rate, and no forfeiture rate. Effective October 4, 2021, the Company approved the granting of options under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval the Company granted stock options to purchase 73,360 shares of common stock to an employee in exchange for services provided to the Company and/or its subsidiaries. These options vest over two years with 36,680 shares vesting on October 4, 2022, and 36,680 shares vesting on October 4, 2023, subject to continued service by the optionee, and expire 10 years from the date of grant with an exercise price of $3.40 per share. The actual number of options that are eligible for the time-based vesting is contingent upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents. The Company has calculated the estimated fair market value of these options at $128,003, using the Black-Scholes model and the following assumptions: term 5.5 years, stock price $3.04 exercise price $3.40, 68.80% volatility, 1.49% risk free rate, and no forfeiture rate. Below is a table summarizing the options issued and outstanding as of December 31, 2022, all of which were issued pursuant to the 2011 Plan (for option issuances prior to 2016) or the 2015 Plan (for option issuances commencing in 2016)and which have a weighted average exercise price of $3.87 per share and an aggregate weighted average remaining contractual life of 5.22 years. Weighted Average Proceeds to Exercise Remaining Company if Number Number Price Contractual Life Exercised Outstanding Exercisable ($) (Years) $ 635,000 635,000 3.25 2.12 2,063,750 2,717 2,717 3.35 0.67 9,102 1,022,587 532,493 3.40 8.32 3,476,796 795,000 795,000 3.60 6.94 2,862,000 1,682,837 1,682,837 4.00 3.76 6,731,348 11,801 11,801 4.35 0.44 51,334 89,163 89,163 4.38 5.07 390,534 50,000 50,000 4.80 4.01 240,000 696,000 696,000 5.00 4.24 3,480,000 4,985,105 4,495,011 19,304,864 Stock-based compensation expense related to stock options of $1,127,502 and $1,069,605 was recorded for the year ended December 31, 2022 and December 31, 2021 respectively. Total remaining unrecognized compensation cost related to non-vested stock options is approximately $287,363 and is expected to be recognized over a period of 0.76 years. As of December 31, 2022, the total intrinsic value of stock options was $nil. As of December 31, 2022, an aggregate of 417,318 shares of common stock remained available for future issuance under the 2015 Plan. c ) Restricted Stock Units (RSUs) Below is a table summarizing the RSUs issued and outstanding as of December 31, 2022, all of which were issued pursuant to the 2015 Plan. Weighted Average Number of Exercise Price RSUs $ Outstanding at December 31, 2020 67,500 3.47 Granted 789,500 3.33 Vested (31,250 ) 3.55 Cancelled (15,000 ) 3.3 Outstanding at December 31, 2021 810,750 3.33 Granted 1,892,102 1.64 Vested (377,007 ) 3.33 Cancelled (62,937 ) 2.88 Outstanding at December 31, 2022 2,262,908 2.05 2022 Below is a table summarizing the RSUs granted during the year ended December 31, 2022, all of which were issued pursuant to the 2015 Plan. These RSUs vest equally over periods stated on the dates noted, subject to continued service, and will result in the compensation expense stated. The exception to this is specified in note (iv) which is described in detail below. Equity First Second Third RSU Incentive RSUs Grant Vesting Vesting Vesting Vesting Expense Note Plan # Date Period Date Date Date $ 2015 8,000 Feb 8, 2022 24 Months Feb 8, 2023 Feb 8, 2024 N/A 22,640 2015 30,000 Mar 1, 2022 24 Months Mar 1, 2023 Mar 1, 2024 N/A 84,300 2015 32,000 Apr 4, 2022 24 Months Apr 4, 2023 Apr 4, 2024 N/A 94,400 2015 104,000 Apr 4, 2022 36 Months Apr 4, 2023 Apr 4, 2024 Apr 4, 2025 306,800 2015 33,000 Jun 1, 2022 24 Months Jun 1, 2023 Jun 1, 2024 N/A 80,850 2015 63,102 Aug 15, 2022 24 Months Aug 15, 2023 Aug 15, 2024 N/A 126,835 2015 25,000 Sep 21, 2022 24 Months Sep 21, 2023 Sep 21, 2024 N/A 42,250 (iii) 2015 1,144,000 Oct 4, 2022 36 Months Oct 4, 2023 Oct 4, 2024 Oct 4, 2025 1,670,240 (iv) 2015 450,000 Oct 4, 2022 Up to 42 Months Variable Variable Variable 321,078 (v) 2015 3,000 Nov 29, 2022 36 Months Nov 29, 2023 Nov 29, 2024 Nov 29, 2025 6,450 1,892,102 2,755,843 (iii) These RSUs vest upon the achievement of corporate goals focused around product development and commercialization with further time-based vesting, subject to continued service of the award recipient to the Company through the applicable vesting dates. On October 13, 2022, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain corporate goals previously established by the Compensation Committee, which resulted in the vesting of the rights with respect to an aggregate of 198,275 RSUs. The RSUs are further subject to a three-year time based vesting schedule, vesting in three equal installments on the dates set forth in the table above, and conditioned upon the recipient’s continued service through the applicable vesting date. On January 12, 2023, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain additional corporate goals, which resulted in the vesting of the rights with respect to an aggregate of an additional 424,875 RSUs, subject to the foregoing time-based vesting and conditioned upon the recipient’s continued service through the applicable vesting date. (iv) These RSUs vest upon the share price closing above $5.00 per share for a minimum of ten consecutive trading days within a period of three years from the date of grant, with further time-based vesting in a single installment six months after the timely achievement of the target, if at all, and subject to continued service. The estimated fair value of the RSUs that include a market vesting condition will be measured on the grant date using a Monte Carlo Simulation of a Geometric Brownian Motion stock path model and incorporating the probability of vesting occurring. The estimated fair value of these awards will be recognized over the derived service period (as determined by the valuation model), with such recognition occurring regardless of whether the market condition is met. (v) The Company granted an aggregate of 3,000 RSUs on November 29, 2022 as an employment inducement award. These RSUs are subject to time-based vesting and subject to the continued service of each recipient. Below is a table summarizing the RSUs vested during the year ended December 31, 2022, all of which were issued pursuant to the 2015 Plan. Equity Incentive RSUs Vest Shares Shares Withheld for Plan # Date Issued Taxes 2015 15,000 Mar 25, 2022 15,000 - 2015 26,250 Apr 13, 2022 21,712 4,538 2015 50,000 May 1, 2022 35,000 15,000 2015 230,102 Aug 3, 2022 191,992 38,110 2015 12,000 Sep 7, 2022 7,038 4,962 2015 19,905 Oct 4, 2022 13,022 6,883 2015 21,750 Nov 1, 2022 12,344 9,406 2015 2,000 Dec 15, 2022 1,181 819 377,007 297,289 79,718 Below is a table summarizing the RSUs cancelled during the year ended December 31, 2022, all of which were originally issued pursuant to the 2015 Plan. Equity Incentive RSUs Cancellation RSUs Plan # Date Cancelled 2015 33,000 May 31, 2022 33,000 2015 1,365 Aug 18, 2022 1,365 2015 17,572 Nov 18, 2022 17,572 2015 11,000 Nov 21, 2022 11,000 62,937 62,937 2021 Below is a table summarizing the RSUs granted during the year ended December 31, 2021, all of which were issued pursuant to the 2015 Plan. Equity Incentive RSUs Grant Vesting First Vesting Second Vesting Third Vesting RSU Expense Note Plan # Date Period Date Date Date $ 2015 5,000 Jan 1, 2021 - Jan 1, 2021 N/A N/A 19,450 2015 30,000 Mar 25, 2021 24 Months Mar 25, 2022 Mar 25, 2023 N/A 107,700 2015 150,000 May 1, 2021 36 Months May 1, 2022 May 1, 2023 May 1, 2024 496,500 (i) 2015 460,191 Aug 3, 2021 24 Months Aug 3, 2022 Aug 3, 2023 N/A 1,523,232 2015 38,000 Sep 7, 2021 24 Months Sep 7, 2022 Sep 7, 2023 N/A 126,160 (ii) 2015 39,809 Oct 4, 2021 24 Months Oct 4, 2022 Oct 4, 2023 N/A 121,019 2015 43,500 Nov 1, 2021 24 Months Nov 1, 2022 Nov 1, 2023 N/A 152,685 2015 23,000 Dec 15, 2021 24 Months Dec 15, 2022 Dec 15, 2023 N/A 77,740 789,500 2,624,486 (i) Effective August 3, 2021, the Company approved the granting of RSUs under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted RSUs of 460,191 shares of common stock to various personnel (including directors, executives, members of management and employees of the Company and/or its subsidiaries) in exchange for services provided to the Company and/or its subsidiaries. The actual number of RSUs that are eligible for the time-based vesting is contingent based upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents as well as continued service by the participant through the applicable vesting date. The RSUs eligible for vesting shall vest over two years with up to 230,102 units vesting on August 3, 2022, and up to 230,089 units vesting on August 3, 2023 and will result in total compensation expense of $1,523,232. (ii) Effective October 4, 2021, the Company approved the granting of RSUs under the 2015 Plan vesting upon achievement of certain corporate goals (see additional details in Note 10 (h)). Pursuant to this approval, the Company granted RSUs of 39,809 shares of common stock to an employee of the Company and/or its subsidiaries in exchange for services provided to the Company and/or its subsidiaries. The actual number of RSUs that are eligible for the time-based vesting is contingent based upon the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents as well as continued service by the participant through the applicable vesting date. These RSUs vest over two years with 19,905 units vesting on October 4, 2022, and 19,904 units vesting on October 4, 2023, subject to continued service and will result in total compensation expense of $121,019. Below is a table summarizing the RSUs vested during the year ended December 31, 2021, all of which were issued pursuant to the 2015 Plan. Equity Incentive RSUs Vest Plan # Date Shares Issued Shares Withheld for Taxes 2015 5,000 Jan 1, 2021 3,000 2,000 2015 26,250 Apr 13, 2021 21,712 4,538 31,250 24,712 6,538 Below is a table summarizing the RSUs cancelled during the year ended December 31, 2021, all of which were originally issued pursuant to the 2015 Plan. RSUs Equity Incentive Plan # Vest Date RSUs Cancelled 2015 15,000 Dec 31, 2020 15,000 15,000 15,000 Below is a table summarizing the RSUs issued and outstanding as of December 31, 2022 of which the last to vest have a remaining contractual life of 3.26 years. Weighted Average Weighted Average Grant date Remaining Number Fair Value Contractual Life Outstanding $ (Years) 450,000 0.69 3.26 1,133,000 1.46 1.76 25,000 1.69 1.22 63,102 2.01 1.08 3,000 2.15 1.91 33,000 2.45 0.92 30,000 2.81 0.67 8,000 2.83 0.61 136,000 2.95 0.97 19,904 3.04 0.38 311,152 3.31 0.59 12,000 3.32 0.68 2,000 3.38 0.48 21,750 3.51 0.42 15,000 3.59 0.23 2,262,908 Stock-based compensation expense related to RSUs of $1,903,054 and $898,910 was recorded in the years ended December 31, 2022, and December 31, 2021, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $2,214,593.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Taxes
Income Taxes	Note 9 - Income Taxes The Company has estimated net operating losses for the years ended December 31, 2022 and 2021 of $28.6 million and $24.4 million, respectively, available to offset taxable income in future years. The significant components of deferred income taxes and assets as of December 31, 2022 and December 31, 2021 are as follows: December 31, 2022 December 31, 2021 Net Deferred Tax Liability $ $ Excess of tax over book depreciation and amortization (46,001 ) (8,330 ) ROU Asset (117,134 ) (28,657 ) Lease Liability 122,279 47,301 Accrued expenses 5,655 1,199 Unrealized Gain/Loss - 103,106 Capitalized research expenses 1,237,122 - Stock-based compensation 321,956 186,252 Net Operating Losses carry-forward 28,556,992 24,390,040 Research and development tax credits 769,317 606,729 Gross deferred tax assets 30,850,186 25,297,640 Valuation allowance (30,850,186 ) (25,297,640 ) Net deferred tax asset - - Change in Valuation Allowance (5,552,546 ) December 31, 2022 December 31, 2021 Summary Rate Reconciliation % % Federal statutory rate 21.0 21.0 State income taxes, net of federal benefit - - Permanent Differences (0.6 ) (4.8 ) Stock based compensation (0.3 ) (0.6 ) Federal Research & Development Credits 0.7 0.5 Foreign taxes (0.1 ) 1.5 Federal Deferred Rate Decrease 0.5 (14.4 ) Change in Valuation Allowance (21.2 ) (3.2 ) Total - - Disclosure Amounts December 31, 2022 Net Operating Losses - United States 35,072,965 Net Operating Losses - Foreign 90,614,447 Credit Carryforward - United States - Credit Carryforward - Foreign 769,317 Increase in Valuation Allowance 5,552,546

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies
Commitments And Contingencies	Note 10 - Commitments and Contingencies a) Finance Lease Obligations In 2016, the Company entered into a real estate capital lease with ING Asset Finance Belgium S.A. (“ING”) to purchase a property located in Belgium for €1.12 million, maturing May 2031, with implicit interest of 2.62%. As of December 31, 2022, the balance payable was $482,146. In 2018, the Company entered into a capital lease with BNP Paribas leasing solutions to purchase a freezer for the Belgium facility for €25,000, maturing January 2022, with implicit interest of 1.35%. The leased equipment is amortized on a straight-line basis over 5 years. As of December 31, 2022, the balance payable was $0. The following is a schedule showing the future minimum lease payments under financing leases by years and the present value of the minimum payments as of December 31, 2022. 2023 $ 57,726 2024 $ 57,725 2025 $ 57,725 2026 $ 57,726 2027 $ 57,726 Greater than 5 years $ 252,534 Total $ 541,162 Less: Amount representing interest $ (59,016 ) Present value of minimum lease payments $ 482,146 b) Operating Lease Right-of-Use Liabilities As of December 31, 2022, operating lease right-of-use assets and liabilities arising from operating leases were $619,392 and $645,254, respectively. During the year ended December 31, 2022, cash paid for amounts included for the measurement of lease liabilities was $245,354 and the Company recorded operating lease expense of $267,434. Our weighted average discount rate is 2.38% and the weighted average remaining lease term is 25 months. The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of December 31, 2022. 2023 $ 264,799 2024 $ 164,225 2025 $ 120,209 2026 $ 94,600 2027 $ 25,800 Total Operating Lease Obligations $ 669,633 Less: Amount representing interest $ (24,379 ) Present Value of minimum lease payments $ 645,254 The Company’s office space leases are short term, and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the year ended December 31, 2022, $76,955 was recognized in short-term lease costs associated with the office space leases in Singapore and Nevada. The annual payments remaining for such short-term office leases as of December 31, 2022, were as follows: 2023 $ 27,069 2024 - 2027 $ - Total Operating Lease Liabilities $ 27,069 c) Grants Repayable In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €1,048,020. Per the terms of the agreement, €314,406 of the grant is to be repaid by installments over the period from June 30, 2014 to June 30, 2023. The Company has recorded the balance of €733,614 to other income in previous years as there is no obligation to repay this amount. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is twice the amount of funding received. As of December 31, 2022, the grant balance repayable was $26,831. In 2018, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €605,000. Per the terms of the agreement, €181,500 of the grant is to be repaid by instalments over 12 years commencing in 2020. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received. As of December 31, 2022, the grant balance repayable was $107,280. In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for €495,000. Per the terms of the agreement, €148,500 of the grant is to be repaid by installments over 10 years commencing in 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received. As of December 31, 2022, the grant balance repayable was $97,799. In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for €929,433. Per the terms of the agreement, €278,830 of the grant is to be repaid by instalments over 15 years commencing in 2022. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received. As of December 31, 2022, the grant balance repayable was $230,392. As of December 31, 2022, the balance repayable was $462,302 and the annual payments remaining were as follows: 2023 $ 49,283 2024 $ 26,541 2025 $ 34,581 2026 $ 42,026 2027 $ 45,978 Greater than 5 years $ 263,893 Total Grants Repayable $ 462,302 d) Long-Term Debt In 2016, the Company entered into a 7-year loan agreement with Namur Invest for €440,000 with a fixed interest rate of 4.85%, maturing December 2023. As of December 31, 2022, the principal balance payable was $82,659. In 2016, the Company entered into a 15-year loan agreement with ING for €270,000 with a fixed interest rate of 2.62%, maturing December 2031. As of December 31, 2022, the principal balance payable was $188,806. In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to €1 million with a fixed interest rate of 4.50%, maturing September 2024. As of December 31, 2022, €1 million has been drawn down under this agreement and the principal balance payable was $482,954. In 2018, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 with fixed interest rate of 4.00%, maturing June 2022. As of December 31, 2022, the principal balance payable was $0. In 2019, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 with fixed interest rate of 4.80%, maturing September 2024. As of December 31, 2022, the principal balance payable was $279,548. In 2020, the Company entered into a 10-year loan agreement with Namur Invest for a maximum of €830,000 with fixed interest rate of 4.00%, maturing March 2031. As of December 31, 2022, the amount that has been drawn down under this agreement was €707,599, representing a principal balance payable of $759,419. On November 23, 2021, the Company entered into a 3 ½ year loan agreement with SOFINEX for a maximum of €450,000 with fixed interest rate of 5.00%, maturing June 2025. As of December 31, 2022, the amount that has been drawn down under this agreement was €450,000, representing a principal balance payable of $442,708. On February 5, 2022 the Company entered into a 9-month loan agreement with First Insurance Funding for a maximum of $620,549 with fixed interest rate of 3.57%, maturing November 2022. As of December 31, 2022, the principal balance payable was $0. On August 16, 2022, the Company entered into a 4-year loan agreement with Namur Invest for a maximum of €1,000,000 with fixed interest rate of 6.00%, maturing July 2026. As of December 31, 2022, the amount that has been drawn down under this agreement was €1,000,000, representing a principal balance payable of $1,073,231. On November 18, 2022, the Company entered into a 4-year loan agreement with Namur Invest for a maximum of €500,000 with fixed interest rate of 5.45%, maturing December 2027. As of December 31, 2022, the amount that has been drawn down under this agreement was €500,000, representing a principal balance payable of $536,615. As of December 31, 2022, the total balance for long-term debt payable was $3,845,940 and the payments remaining were as follows: 2023 $ 1,268,528 2024 $ 1,138,227 2025 $ 704,312 2026 $ 480,358 2027 $ 281,602 Greater than 5 years $ 446,799 Total $ 4,319,826 Less: Amount representing interest $ (473,886 ) Total Long-Term Debt $ 3,845,940 e) Collaborative Agreement Obligations In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a 3-year period for a cost to the Company of up to $2.55 million payable over such period. As of December 31, 2022, $510,000 is still to be paid by the Company under this agreement. In 2019, the Company entered into a funded sponsored research agreement with the Texas A&M University (“TAMU”) in consideration for the license granted to the Company for a 5-year period for a cost to the Company of up to $400,000 payable over such period. As of December 31, 2022, $0 is still to be paid by the Company under this agreement. In 2020, the Company entered into a research agreement for the bioinformatic analysis of cell-free DNA fragments from whole-genome sequencing with the Hebrew University of Jerusalem for six months for a cost to the Company of €54,879. Subsequently the parties entered into an amendment to the agreement with an additional cost to the Company of €100,236. In the year ended December 31, 2022, the parties entered into agreements for an additional cost to the Company of €39,000. As of December 31, 2022, $23,018 is still to be paid by the Company under the amended agreement. On August 2, 2022, the Company entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps (“NETs”) in cancer patients with sepsis for a cost to the Company of $346,787. As of December 31, 2022, $346,787 is still to be paid by the Company under this agreement. As of December 31, 2022, the total amount to be paid for future research and collaboration commitments was approximately $879,805 and the annual payments remaining were as follows: 2023 $ 798,032 2024 - 2027 $ 81,773 Total Collaborative Agreement Obligations $ 879,805 f) Other Commitments Volition Vet On October 25, 2019, the Company entered into an agreement with TAMU for provision of in-kind services of personnel, animal samples and laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet with an additional 5%, vesting in a year from the date of the agreement, giving TAMU in aggregate, a 12.5% equity interest as of such date. As of December 31, 2022, TAMU has a 12.5 % equity interest in Volition Vet. Volition Germany On January 10, 2020, the Company, through its wholly-owned subsidiary Belgian Volition, acquired an epigenetic reagent company, Octamer GmbH (“Octamer”), based in Munich, Germany, and hired its founder for his expertise and knowledge to be passed to Company personnel. On March 9, 2020, Octamer was renamed to Volition Germany GmbH (or “Volition Germany”). In connection with the transaction agreement, the Company entered into a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of five years post-closing. As of December 31, 2022, $210 is payable under the 6% royalty agreement on sales to date towards the Company’s aggregate minimum royalty obligation of $118,055. Volition America On November 3, 2020, the Company entered into a professional services master agreement (the “Master Agreement”) with Diagnostic Oncology CRO, LLC (“DXOCRO”) to conduct a pivotal clinical trial and provide regulatory submission and reimbursement related services. On August 8, 2022, the Company and DXOCRO amended and restated the Master Agreement to expand the scope of DXOCRO’s consultant services provided thereunder (the “A&R Master Agreement”). The A&R Master Agreement requires DXOCRO to support development and clinical validation studies for the Company’s Nu.Q® product portfolio in the United States, including by conducting large-scale finding studies across multiple sites in the U.S. using Nu.Q® NETs and Nu.Q® Cancer tests to determine clinical utility in sepsis and non-Hodgkin’s lymphoma. The Company anticipates DXOCRO’s services under the agreement will be completed by the end of the third quarter 2023 at a total cost to the Company of up to $4.2 million. The Company’s payment obligations accrue upon delivery of projects under the agreement. The Company may terminate the agreement or any project thereunder upon at least 30 days’ prior written notice. Unless earlier terminated, the A&R Master Agreement terminates on the later of December 31, 2025 or the date upon which all services have been completed. As of December 31, 2022, $ 264,692 is payable under the A&R Master Agreement, and up $3,435,165 may be payable by Company in future periods for services rendered. g) Legal Proceedings There are no legal proceedings which the Company believes will have a material adverse effect on its financial position. h) Commitments in Respect of Corporate Goals and Performance-Based Awards In August 2021 and October 2021, the Compensation Committee of the Board of Directors approved the granting of equity-based awards under the 2015 Plan as well as cash bonuses, vesting upon achievement of certain corporate goals focused around product development and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries. On June 23, 2022, the Compensation Committee of the Board of Directors approved the achievement of all of the remaining outstanding corporate goals related to the awards in August 2021 and October 2021 resulting in the payment of the cash bonus awards and the vesting of the remaining rights to the equity-based awards, which equity-based awards remain subject to time-based vesting in equal installments on each of August 3, 2022 and August 3, 2023 (with the exception of October 4, 2022 and October 4, 2023 for one award) and the continuous service of the award recipient through the applicable vesting date. As of December 31, 2022, the Company has paid compensation expense of $737,137 in relation to the July 1, 2022 specified corporate goals based on the actual outcomes related to the prescribed performance targets. In October 2022, the Compensation Committee of the Board of Directors approved the granting of cash bonuses, payable upon achievement of various corporate goals focused around product development, manufacturing, financing and commercialization, to various personnel including directors, executives, members of management, consultants and employees of the Company and/or its subsidiaries. Conditional upon the achievement by January 1, 2023 and July 1, 2023 of all specified corporate goals as set forth in the minutes of the Compensation Committee, as well as continued service by the award recipients, the Company at the sole discretion of the Chief Executive Officer and the Chief Financial Officer would pay a cash bonus to such award recipients. As of December 31, 2022, the Company has accrued compensation expense of $905,856 in relation to the January 1, 2023 and July 1, 2023 specified corporate goals based on the actual outcomes related to the prescribed performance targets. As discussed in detail in Note 8, - Stock-Based Compensation, As of December 31, 2022, the Company has recognized compensation expense of $969,593 in relation to the options vested in 2022 and $630,863 in relation to the options that will vest in 2023. The Company has unrecognized compensation expense of $270,550 to such stock options, based on the outcomes related to the prescribed performance targets on the outstanding awards. Total Amortised Amortised Un-Amortised Award 2022 2021 2023 $ $ $ $ 969,593 580,411 389,182 - 630,863 450,090 180,773 270,550 h) Commitments in Respect of Corporate Goals and Performance-Based Awards (continued) As of December 31, 2022, the Company has recognized compensation expense of $822,149 in relation to the RSUs fully vested in 2022 and $530,930 in relation to RSUs that will vest in 2023. The Company has unrecognized compensation expense of $228,491 to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards. Total Amortised Amortised Un-Amortised Award 2022 2021 2023 $ $ $ $ 822,149 493,207 328,942 - 530,930 379,191 151,739 228,491 As of December 31, 2022, the Company has recognized total compensation expense of $245,861 of which $134,087 in relation to RSUs that will vest in 2023, $65,088 in relation to RSUs that will vest in 2024, and $46,686 in relation to RSUs that will vest in 2025. The Company has unrecognized compensation expense of $1,408,319 in relation to such RSUs, based on the outcomes related to the prescribed performance targets on the outstanding awards. Vesting Amortised Year 2022 Un-Amortised $ $ 2023 134,087 417,327 2024 65,088 470,244 2025 46,686 520,748 245,861 1,408,319

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events
Subsequent Events	Note 11 - Subsequent Events Common Stock Issuances and Repurchases From January 1 to January 19, 2023, the Company raised aggregate net proceeds (net of broker commissions and fees) of approximately $656,000 under the 2022 EDA through the sale of 279,703 shares of its common stock. No additional shares have been sold under the 2022 EDA through March 8, 2023. On January 5, 2023, the Company purchased from a former officer 13,264 shares of its common stock at $2.39 per share, for a total cost to the Company of $31,772.66. These shares were subsequently retired. RSU Vesting On January 12, 2023, the Compensation Committee of the Board of Directors approved the satisfactory achievement of certain corporate goals established by the Compensation Committee on October 4, 2022, which resulted in the vesting of rights with respect to an aggregate of 424,875 RSUs. The RSUs are further subject to a 3-year time based vesting schedule, vesting in three equal installments on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively, and conditioned upon the recipient’s continued service through the applicable vesting date. On February 8, 2023, 4,000 RSUs previously granted to an employee vested and resulted in the issuance of 2,369 shares of common stock and the remaining 1,631 shares of common stock were withheld as taxes and returned to the 2015 Plan. On March 1, 2023, 15,000 RSUs previously granted to employees vested and resulted in the issuance of 9,609 shares of common stock. An aggregate of 5,391 shares of common stock were withheld as taxes and returned to the 2015 Plan. Capital Raise On February 17, 2023, the Company entered into an underwriting agreement with Newbridge in connection with an underwritten public offering of 4,945,000 shares of the Company’s common stock, which includes Newbridge’s exercise in full of its overallotment option, pursuant to the Company’s 2021 Form S-3. Newbridge purchased the shares from the Company at a price of $1.6275 per share. The offering closed on February 22, 2023. The Company received net proceeds of approximately $8.0 million from the offering before deducting offering expenses payable by the Company. Commercial Product Launches On January 12, 2023, the Company announced the availability of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories, Inc. reference laboratory network in the U.S. On February 16, 2023, the Company announced that its Nu.Q® Vet Cancer Test was available for pre-order to veterinarians at the point of care through Heska.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Summary of Significant Accounting Policies
Basis Of Presentation	The consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP and are expressed in US dollars. The Company’s fiscal year end is December 31.
Use Of Estimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets and valuations of stock-based compensation. The Company bases its estimates and assumptions on current facts, historical experiences and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.
Principles Of Consolidation	The accompanying consolidated financial statements for the year ended December 31, 2022 include the accounts of the Company and its subsidiaries. The Company has two wholly owned subsidiaries, Singapore Volition Pte. Limited and Volition Global Services SRL. Singapore Volition has one wholly owned subsidiary, Belgian Volition SRL. Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited, Volition America, Inc, Volition Germany GmbH, and its one majority owned subsidiary Volition Veterinary Diagnostics Development LLC. See Note 10 (f), Commitments and Contingencies – Other Commitments
Cash And Cash Equivalents	The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,867,050 and $20,581,313, respectively, in cash and cash equivalents. As of December 31, 2022, and December 31, 2021, the Company had $10,079,089 and $19,753,878, respectively, in its domestic accounts in excess of Federal Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $1,725,981 and $134,134, respectively, in its foreign accounts in excess of the Belgian Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $100,601 and $102,514, respectively, in its foreign accounts in excess of the Singapore Deposit insured limits. As of December 31, 2022, and December 31, 2021, the Company had $326,631 and $142,410, respectively, in its foreign accounts in excess of the UK Deposit insured limits.
Accounts Receivables	Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of December 31, 2022, the accounts receivable balance was $72,609 and the allowance for doubtful accounts was $nil.
Property and Equipment	Property and equipment are stated at historical cost and depreciated over the useful life of the asset using the straight-line method. Useful lives are assigned to assets depending on their category. For details regarding property and equipment, refer to Note 4.
Basic And Diluted Net Loss Per Share	The Company computes net loss per share in accordance with Accounting Standards Codification (“ASC”) 260, “Earnings Per Share,”
Foreign Currency Translation	The Company has functional currencies in Euros, US Dollars and British Pounds Sterling and its reporting currency is the US Dollar. Management has adopted ASC 830-20, “Foreign Currency Matters – Foreign Currency Transactions”
Financial Instruments	Pursuant to ASC 820, “ Fair Value Measurements and Disclosures,” Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable, accrued liabilities, notes payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consists of quoted prices in active markets for identical assets. The Company believes that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Other Comprehensive Income (Loss)	ASC 220, “ Other Comprehensive Income/(Loss)”,
Income Taxes	Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740, “Accounting for Income Taxes”
Revenue Recognition	The Company adopted ASC 606, “ Revenue from Contracts with Customers,” The Company generates product revenues from the sale of its Nu.Q ® Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows: Royalty The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented under “Royalty” under the consolidated statements of operations. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known. Product The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in “Product” in the consolidated statements of operations and comprehensive loss. Service The Company includes revenue recognized from laboratory services performed in the Company’s laboratory on behalf of third parties under “Service” under the consolidated statements of operations. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. Licensing The Company includes revenue recognized from the licensing of certain rights to third parties in “Licensing” in the consolidated statements of operations and comprehensive loss. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. Revenue from Heska License Agreement On March 28, 2022, Belgian Volition entered into a Master License and Supply Agreement (the “License Agreement”) with Heska Corporation (“Heska”), pursuant to which Belgian Volition granted Heska worldwide exclusive rights to sell the Nu.Q® Vet Cancer Test at the point of care (“POC”) initially for the screening of lymphoma and hemangiosarcoma in dogs (“Canine Lymphoma & HSA”), and non-exclusive rights to sell its Nu.Q® Vet Cancer Test in kit format (“Kits”) through Heska’s network of central reference laboratories (“Central Lab”) initially for Canine Lymphoma & HSA. Under and subject to the terms of the License Agreement, Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines. The License Agreement contains additional time-based triggers for the payment of the above-described milestones as well. Any further expansion of the License Agreement to cover other cancer and non-cancer indications is subject to negotiation between the parties. Belgian Volition will also supply Central Lab Kits and will receive a pre-agreed price per test, adjusted annually for inflation. The price per test for POC key components (“Key Components”) is also discounted to reflect the lower cost to Belgian Volition and additional assembly costs for Heska, as well as consideration for Heska’s upfront and milestone payments. Heska will assemble the Key Components for use at the POC, and is additionally responsible for marketing and distribution efforts and related costs. The License Agreement may be terminated by either party for a material breach by the other party, subject to notice and cure provisions, or in the event of the other party’s insolvency. Heska also has the option to terminate if it is unable to adapt the Key Components for use on a POC platform. Unless earlier terminated, the License Agreement will continue in effect for an initial term of 22 years for POC and 5 years for Central Lab, with the Central Lab term then continuing on a rolling one-year basis for the POC term. According to ASC Topic 606, “ Revenue from Contracts with Customers In conjunction with the License Agreement, the Company evaluated whether or not the performance obligations granted under the License Agreement were distinct and concluded that they were not distinct as Heska could not benefit from the license without the supply (manufacturing) services. The supply services are highly specialized and are dependent on the supply of the product from the Company. As such, the performance obligations granted under the License Agreement were combined to constitute a single performance obligation and the Company accounts for them as a single contract. During the first quarter of 2022, the Company received a $10.0 million upfront payment under the License Agreement, which is included as deferred revenue on the accompanying consolidated balance sheet as of December 31, 2022. The Company allocated the upfront payment and any milestone payments that were not constrained to the single performance obligation in the contract. The Company expects to recognize the $10.0 million upfront payment and any milestone amounts not constrained under the License Agreement over time using an output method based on Key Components and Kits supplied to Heska. As of December 31, 2022, the remaining $18.0 million in milestone payments under the License Agreement remains constrained and will not begin to be recognized until such amount becomes unconstrained. In determining the transaction price, the Company analyzed the variable consideration and whether or not such variable consideration was constrained. The Company will reassess this variable consideration at each reporting period and adjust the transaction price, if necessary. The total Key Components and Kits that the Company expects to manufacture for Heska over the life of the contract will be a significant judgment in recognizing revenue once the Company begins to supply product to Heska.
Deferred Revenue (contract Liabilities) And Contract Assets	Deferred revenue consists of amounts for which the Company has an unconditional right to bill, and/or amounts for which payment has been received (including non-refundable amounts) but have not been recognized as revenue because the related performance obligations are deemed incomplete. As of December 31, 2022, the Company recorded $10.0 million as deferred revenue in respect of a non-refundable payment received in relation to a licensing and product supply agreement with Heska Corporation. As of December 31, 2021, the Company recorded $12,512 as deferred revenue. Contract assets include costs and services incurred on contracts with open performance obligations. These contract assets were immaterial as of December 31, 2022.
Research And Development	In accordance with ASC 730, the Company follows the policy of expensing its research and development costs in the period in which they are incurred. The Company incurred research and development expenses of $14.6 million and $13.0 million during the years ended December 31, 2022 and 2021, respectively.
Impairment of Long-Lived Assets	In accordance with ASC 360, “Property Plant and Equipment”,
Stock-based Compensation	The Company records stock-based compensation in accordance with ASC 718, “ Compensation – Stock Compensation”
Leases	The Company accounts for leases in accordance with ASC Topic 842, “Leases.” The Company determines whether a contract is a lease at contract inception or for a modified contract at the modification date. At inception or modification, the Company recognizes right-of-use assets (“ROU”) and related lease liabilities on the balance sheet for all leases greater than one year in duration. Lease liabilities and their corresponding ROU assets are initially measured at the present value of the unpaid lease payments as of the lease commencement date. If the lease contains a renewal and/or termination option, the exercise of the option is included in the term of the lease if the Company is reasonably certain that a renewal or termination option will be exercised. As the Company’s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate (“IBR”) based on the information available at the commencement date of the respective lease to determine the present value of future payments. The IBR is determined by estimating what it would cost the Company to borrow a collateralized amount equal to the total lease payments over the lease term based on the contractual terms of the lease and the location of the leased asset. Operating lease payments are recognized as an expense on a straight-line basis over the lease term in equal amounts of rent expense attributed to each period during the term of the lease, regardless of when actual payments are made. This generally results in rent expense in excess of cash payments during the early years of a lease and rent expense less than cash payments in later years. The difference between rent expense recognized and actual rental payments is typically represented as the spread between the ROU asset and lease liability. When calculating the present value of minimum lease payments, we account for leases as one single lease component if a lease has both lease and non-lease fixed cost components. Variable lease and non-lease cost components are expensed as incurred. We do not recognize ROU assets and lease liabilities for short-term leases that have an initial lease term of 12 months or less. We recognize the lease payments associated with short-term leases as an expense on a straight-line basis over the lease term.
Covid-19 Pandemic Impact	As of the date of this filing, there continue to be widespread concerns regarding the ongoing impacts and disruptions caused by the COVID-19 pandemic in the regions in which the Company operates. As a result of the impacts of the COVID-19 pandemic, the Company has experienced and may continue to experience disruptions to its clinical trials, including patient enrollment and sample collection delays. Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic, the extent to which the pandemic will impact its business, financial condition, and results of operations in future periods is highly uncertain and will be affected by a number of factors outside of the Company’s control. These include the duration and extent of the COVID-19 pandemic, the development of new variants of the COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and mitigation measures, the effect of government stabilization and recovery efforts, and the success of vaccine distribution programs.
Recent Accounting Pronouncements	The Company receives funding from public bodies for a proportion of the costs of specific projects. Funds are received in line with claims submitted for the agreed expenditure. The Company recognizes grant income once claims submitted are approved and funds are received. General working capital funding received at the commencement of a project is treated as deferred income and is recorded in accrued liabilities until it has been utilized for the expenditure claimed. Funding received that is repayable is shown as a liability. The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU amends ASC 805 to require acquiring entities to apply ASC 606 to recognize and measure contract assets and contract liabilities in business combinations. The standard is effective for the Company's fiscal year beginning January 1, 2023, with early adoption permitted. The adoption of this standard is not expected to have a material effect on our financial position, results of operations, or cash flows.

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property and Equipment
Schedule Of Property And Equipment	December 31, 2022 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 656,759 497,306 159,453 Laboratory equipment 5 years 4,190,289 1,951,387 2,238,902 Office furniture and equipment 5 years 358,575 239,436 119,139 Buildings 30 years 2,054,332 298,397 1,755,935 Building improvements 5-15 years 1,317,132 326,337 990,795 Land Not amortized 128,788 - 128,788 8,705,875 3,312,863 5,393,012 December 31, 2021 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 599,944 474,169 125,775 Laboratory equipment 5 years 3,032,108 1,434,347 1,597,761 Office furniture and equipment 5 years 293,427 213,244 80,183 Buildings 30 years 2,177,641 243,750 1,933,891 Building improvements 5-15 years 1,293,258 256,309 1,036,949 Land Not amortized 136,518 - 136,518 7,532,896 2,621,819 4,911,077

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2022
Common Stock
Schedule Of share issued from the cashless exercise of options	Date Stock Incentive Plan Stock Options Price Per Share Shares Issued # $ # January 13 - March 19, 2021 2011 7,634 3.35 948 February 2, 2021 2011 20,000 3.80 6,181 February 8, 2021 2011 15,000 4.00 5,769 February 8, 2021 2015 100,000 5.00 19,446 February 8 - February 9, 2021 2015 85,000 4.00 26,357 February 8, 2021 2015 50,000 3.25 18,750 277,634 77,451
Schedule Of share issued from the settlement of RSUs	Date Restricted Stock Units Vested Price Settled Per Share Shares Issued Shares Withheld for Tax # $ # # March 25, 2022 15,000 3.01 15,000 - April 13, 2022 26,250 2.95 21,712 4,538 May 1, 2022 50,000 2.79 35,000 15,000 August 3, 2022 230,102 1.97 191,992 38,110 September 7, 2022 12,000 1.65 7,038 4,962 October 4, 2022 19,905 1.46 13,022 6,883 November 1, 2022 21,750 1.97 12,344 9,406 December 15, 2022 2,000 1.97 1,181 819 377,007 297,289 79,718 Date Restricted Stock Units Vested Price Settled Per Share Shares Issued Shares Withheld for Tax # $ # # January 20, 2021 5,000 4.10 3,000 2,000 April 21, 2021 26,250 3.44 21,712 4,538 31,250 24,712 6,538

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Intangible Assets
Schedule Of Intangible Assets	December 31, 2022 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,104,103 993,598 110,505 December 31, 2021 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,178,135 961,259 216,876
Schedule Of Annual Estimated Amortization	Remaining Remaining Life Amortization 2023 $ 85,636 2024 $ 24,869 Total Intangible Assets $ 110,505

StockBased Compensation (Tables

StockBased Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
StockBased Compensation
Summary Of Changes In Warrants Outstanding	Weighted Average Number of Exercise Price Warrants $ Outstanding at December 31, 2020 175,000 2.75 Granted 310,000 4.52 Exercised - - Expired - - Outstanding at December 31, 2021 485,000 3.88 Granted 54,000 3.05 Exercised - - Expired - - Outstanding at December 31, 2022 539,000 3.80 Exercisable at December 31, 2022 485,000 3.88
Summarizing The Warrants Issued And Outstanding	Weighted Average Proceeds to Exercise Remaining Company if Number Number Price Contractual Exercised Outstanding Exercisable ($) Life (Years) $ 125,000 125,000 2.47 0.15 308,750 54,000 - 3.05 5.76 164,700 50,000 50,000 3.45 3.17 172,500 125,000 125,000 3.95 4.01 493,750 185,000 185,000 4.90 4.09 906,500 539,000 485,000 2,046,200
Summarizes The Changes In Options Outstanding	Weighted Average Number of Exercise Price Options $ Outstanding at December 31, 2020 4,278,619 4.00 Granted 1,090,000 3.41 Exercised (277,634 ) 4.19 Expired/Cancelled (63,467 ) 3.64 Outstanding at December 31, 2021 5,027,518 3.87 Granted - - Exercised - - Expired/Cancelled (42,413 ) 3.43 Outstanding at December 31, 2022 4,985,105 3.87 Exercisable at December 31, 2022 4,495,011 3.93
Summarizing The Options Issued And Outstanding	Weighted Average Proceeds to Exercise Remaining Company if Number Number Price Contractual Life Exercised Outstanding Exercisable ($) (Years) $ 635,000 635,000 3.25 2.12 2,063,750 2,717 2,717 3.35 0.67 9,102 1,022,587 532,493 3.40 8.32 3,476,796 795,000 795,000 3.60 6.94 2,862,000 1,682,837 1,682,837 4.00 3.76 6,731,348 11,801 11,801 4.35 0.44 51,334 89,163 89,163 4.38 5.07 390,534 50,000 50,000 4.80 4.01 240,000 696,000 696,000 5.00 4.24 3,480,000 4,985,105 4,495,011 19,304,864
Summarizing The Rsus Issued And Outstanding Maturity Life	Weighted Average Number of Exercise Price RSUs $ Outstanding at December 31, 2020 67,500 3.47 Granted 789,500 3.33 Vested (31,250 ) 3.55 Cancelled (15,000 ) 3.3 Outstanding at December 31, 2021 810,750 3.33 Granted 1,892,102 1.64 Vested (377,007 ) 3.33 Cancelled (62,937 ) 2.88 Outstanding at December 31, 2022 2,262,908 2.05
summarizing the RSUs issued and outstanding	Weighted Average Weighted Average Grant date Remaining Number Fair Value Contractual Life Outstanding $ (Years) 450,000 0.69 3.26 1,133,000 1.46 1.76 25,000 1.69 1.22 63,102 2.01 1.08 3,000 2.15 1.91 33,000 2.45 0.92 30,000 2.81 0.67 8,000 2.83 0.61 136,000 2.95 0.97 19,904 3.04 0.38 311,152 3.31 0.59 12,000 3.32 0.68 2,000 3.38 0.48 21,750 3.51 0.42 15,000 3.59 0.23 2,262,908
Summary of Amendments to Expiration Dates of Options	Amendment Equity Incentive Stock Options Grant New Expiration Option Expense Note Date Plan # Date Date $ (i) Jul 14, 2021 2011 292,000 Jul 23, 2015 Jul 23, 2025 442,273 Jul 14, 2021 2011 6,367 Mar 20, 2013 Mar 20, 2023 4,151 Jul 14, 2021 2011 8,151 Sep 2, 2013 Sep 2, 2023 6,009 Sep 21, 2021 2015 335,000 Apr 13, 2020 Apr 13, 2030 163,945 (ii) Sep 21, 2021 2015 89,163 Jan 23, 2018 Jan 23, 2028 24,194 (ii) Sep 21, 2021 2015 308,066 Feb 13, 2017 Feb 13, 2027 127,719 Nov 3, 2021 2015 760,000 Apr 15, 2016 Apr 15, 2026 984,511 Nov 3, 2021 2015 15,000 Jun 23, 2016 Jun 23, 2026 19,582 Nov 3, 2021 2015 50,000 Jan 1, 2017 Jan 1, 2027 32,456 Nov 3, 2021 2015 387,934 Mar 30, 2017 Mar 30, 2027 224,901 Nov 3, 2021 2015 615,837 Jan 23, 2018 Jan 23, 2028 213,646 Dec 8, 2021 2015 425,000 Apr 13, 2020 Apr 13, 2030 180,267 Dec 8, 2021 2015 10,000 Dec 1, 2020 Dec 1, 2030 5,209 Dec 8, 2021 2015 40,000 May 20, 2021 May 20, 2031 21,486 3,342,518 2,450,349
Schedule of RSUs granted during period	Equity First Second Third RSU Incentive RSUs Grant Vesting Vesting Vesting Vesting Expense Note Plan # Date Period Date Date Date $ 2015 8,000 Feb 8, 2022 24 Months Feb 8, 2023 Feb 8, 2024 N/A 22,640 2015 30,000 Mar 1, 2022 24 Months Mar 1, 2023 Mar 1, 2024 N/A 84,300 2015 32,000 Apr 4, 2022 24 Months Apr 4, 2023 Apr 4, 2024 N/A 94,400 2015 104,000 Apr 4, 2022 36 Months Apr 4, 2023 Apr 4, 2024 Apr 4, 2025 306,800 2015 33,000 Jun 1, 2022 24 Months Jun 1, 2023 Jun 1, 2024 N/A 80,850 2015 63,102 Aug 15, 2022 24 Months Aug 15, 2023 Aug 15, 2024 N/A 126,835 2015 25,000 Sep 21, 2022 24 Months Sep 21, 2023 Sep 21, 2024 N/A 42,250 (iii) 2015 1,144,000 Oct 4, 2022 36 Months Oct 4, 2023 Oct 4, 2024 Oct 4, 2025 1,670,240 (iv) 2015 450,000 Oct 4, 2022 Up to 42 Months Variable Variable Variable 321,078 (v) 2015 3,000 Nov 29, 2022 36 Months Nov 29, 2023 Nov 29, 2024 Nov 29, 2025 6,450 1,892,102 2,755,843 Equity Incentive RSUs Grant Vesting First Vesting Second Vesting Third Vesting RSU Expense Note Plan # Date Period Date Date Date $ 2015 5,000 Jan 1, 2021 - Jan 1, 2021 N/A N/A 19,450 2015 30,000 Mar 25, 2021 24 Months Mar 25, 2022 Mar 25, 2023 N/A 107,700 2015 150,000 May 1, 2021 36 Months May 1, 2022 May 1, 2023 May 1, 2024 496,500 (i) 2015 460,191 Aug 3, 2021 24 Months Aug 3, 2022 Aug 3, 2023 N/A 1,523,232 2015 38,000 Sep 7, 2021 24 Months Sep 7, 2022 Sep 7, 2023 N/A 126,160 (ii) 2015 39,809 Oct 4, 2021 24 Months Oct 4, 2022 Oct 4, 2023 N/A 121,019 2015 43,500 Nov 1, 2021 24 Months Nov 1, 2022 Nov 1, 2023 N/A 152,685 2015 23,000 Dec 15, 2021 24 Months Dec 15, 2022 Dec 15, 2023 N/A 77,740 789,500 2,624,486
Schedule of RSUs vested during period	Equity Incentive RSUs Vest Shares Shares Withheld for Plan # Date Issued Taxes 2015 15,000 Mar 25, 2022 15,000 - 2015 26,250 Apr 13, 2022 21,712 4,538 2015 50,000 May 1, 2022 35,000 15,000 2015 230,102 Aug 3, 2022 191,992 38,110 2015 12,000 Sep 7, 2022 7,038 4,962 2015 19,905 Oct 4, 2022 13,022 6,883 2015 21,750 Nov 1, 2022 12,344 9,406 2015 2,000 Dec 15, 2022 1,181 819 377,007 297,289 79,718 Equity Incentive RSUs Vest Plan # Date Shares Issued Shares Withheld for Taxes 2015 5,000 Jan 1, 2021 3,000 2,000 2015 26,250 Apr 13, 2021 21,712 4,538 31,250 24,712 6,538
Schedule of RSUs cancelled during period	Equity Incentive RSUs Cancellation RSUs Plan # Date Cancelled 2015 33,000 May 31, 2022 33,000 2015 1,365 Aug 18, 2022 1,365 2015 17,572 Nov 18, 2022 17,572 2015 11,000 Nov 21, 2022 11,000 62,937 62,937 RSUs Equity Incentive Plan # Vest Date RSUs Cancelled 2015 15,000 Dec 31, 2020 15,000 15,000 15,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Taxes
Shedule of components of deferred income taxes and assets	December 31, 2022 December 31, 2021 Net Deferred Tax Liability $ $ Excess of tax over book depreciation and amortization (46,001 ) (8,330 ) ROU Asset (117,134 ) (28,657 ) Lease Liability 122,279 47,301 Accrued expenses 5,655 1,199 Unrealized Gain/Loss - 103,106 Capitalized research expenses 1,237,122 - Stock-based compensation 321,956 186,252 Net Operating Losses carry-forward 28,556,992 24,390,040 Research and development tax credits 769,317 606,729 Gross deferred tax assets 30,850,186 25,297,640 Valuation allowance (30,850,186 ) (25,297,640 ) Net deferred tax asset - - Change in Valuation Allowance (5,552,546 ) December 31, 2022 December 31, 2021 Summary Rate Reconciliation % % Federal statutory rate 21.0 21.0 State income taxes, net of federal benefit - - Permanent Differences (0.6 ) (4.8 ) Stock based compensation (0.3 ) (0.6 ) Federal Research & Development Credits 0.7 0.5 Foreign taxes (0.1 ) 1.5 Federal Deferred Rate Decrease 0.5 (14.4 ) Change in Valuation Allowance (21.2 ) (3.2 ) Total - - Disclosure Amounts December 31, 2022 Net Operating Losses - United States 35,072,965 Net Operating Losses - Foreign 90,614,447 Credit Carryforward - United States - Credit Carryforward - Foreign 769,317 Increase in Valuation Allowance 5,552,546

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies
Schedule Of Future Minimum Lease Payments Under Financing Leases	2023 $ 57,726 2024 $ 57,725 2025 $ 57,725 2026 $ 57,726 2027 $ 57,726 Greater than 5 years $ 252,534 Total $ 541,162 Less: Amount representing interest $ (59,016 ) Present value of minimum lease payments $ 482,146
Schedule Of Future Minimum Lease Payments Under Operating Leases	2023 $ 264,799 2024 $ 164,225 2025 $ 120,209 2026 $ 94,600 2027 $ 25,800 Total Operating Lease Obligations $ 669,633 Less: Amount representing interest $ (24,379 ) Present Value of minimum lease payments $ 645,254
Schedule Of Recognized In Short-term Lease Costs	2023 $ 27,069 2024 - 2027 $ - Total Operating Lease Liabilities $ 27,069
Schedule Of Grants Repayable	2023 $ 49,283 2024 $ 26,541 2025 $ 34,581 2026 $ 42,026 2027 $ 45,978 Greater than 5 years $ 263,893 Total Grants Repayable $ 462,302
Schedule Of Long-term Debt Payable	2023 $ 1,268,528 2024 $ 1,138,227 2025 $ 704,312 2026 $ 480,358 2027 $ 281,602 Greater than 5 years $ 446,799 Total $ 4,319,826 Less: Amount representing interest $ (473,886 ) Total Long-Term Debt $ 3,845,940
Schedule of annual payments Of Collaborative Agreement Obligations	2023 $ 798,032 2024 - 2027 $ 81,773 Total Collaborative Agreement Obligations $ 879,805
Schedule of outcomes related to the prescribed performance targets	Total Amortised Amortised Un-Amortised Award 2022 2021 2023 $ $ $ $ 969,593 580,411 389,182 - 630,863 450,090 180,773 270,550 Total Amortised Amortised Un-Amortised Award 2022 2021 2023 $ $ $ $ 822,149 493,207 328,942 - 530,930 379,191 151,739 228,491 Vesting Amortised Year 2022 Un-Amortised $ $ 2023 134,087 417,327 2024 65,088 470,244 2025 46,686 520,748 245,861 1,408,319

Liquidity and Going Concern A_2

Liquidity and Going Concern Assessment (Details Narrative) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Liquidity and Going Concern Assessment
Net Loss Since Inception	$ 167.3

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash and cash equivalents	$ 10,867,050	$ 20,581,313
Terms of license Agreement	Belgian Volition received an upfront payment of $10.0 million in 2022, and is eligible to receive further milestone payments of (i) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC screening test for Canine Lymphoma & HSA, (ii) $6.5 million upon the first commercial sale by or on behalf of Heska of a POC monitoring test for the same conditions, and (iii) $5.0 million upon the first commercial sale by or on behalf of Heska of a screening or monitoring test for lymphoma in felines
Initial term for POC	22 years
Initial term for Central Lab	5 years
Upfront payment	$ 10,000,000
Milestone amount recognized	18,000,000
Amount in excess of FDIC limit	10,079,089	19,753,878
Accumulated other comprehensive loss	227,097	148,326
Research and development expenses	14,600,000	13,000,000
Impairment losses	0	0
Accounts receivable	72,609	12,510
Deferred revenue	$ 10,000,000	$ 12,512,000,000
Warrants And Options [Member]
Potentially dilutive securities excluded from the computation of EPS	7,787,013	6,323,268
Belgian Deposit Guarantee [Member]
Deposits/cash in excess of insured limits	$ 1,725,981	$ 134,134
Singapore Deposit Insurance [Member]
Deposits/cash in excess of insured limits	100,601	102,514
UK Deposit Protection Scheme [Member]
Deposits/cash in excess of insured limits	$ 326,631	$ 142,410

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cost	$ 8,705,875	$ 7,532,896
Accumulated Depreciation	3,312,863	2,621,819
Net Carrying Value	5,393,012	4,911,077
Land [Member]
Cost	128,788	136,518
Accumulated Depreciation	0	0
Net Carrying Value	128,788	136,518
Computer Hardware And Software [Member]
Cost	656,759	599,944
Accumulated Depreciation	497,306	474,169
Net Carrying Value	$ 159,453	$ 125,775
Useful Life	3 years	3 years
Laboratory Equipment [Member]
Cost	$ 4,190,289	$ 3,032,108
Accumulated Depreciation	1,951,387	1,434,347
Net Carrying Value	$ 2,238,902	$ 1,597,761
Useful Life	5 years	5 years
Office Furniture and Equipment [Member]
Cost	$ 358,575	$ 293,427
Accumulated Depreciation	239,436	213,244
Net Carrying Value	$ 119,139	$ 80,183
Useful Life	5 years	5 years
Buildings [Member]
Cost	$ 2,054,332	$ 2,177,641
Accumulated Depreciation	298,397	243,750
Net Carrying Value	$ 1,755,935	$ 1,933,891
Useful Life	30 years	30 years
Building Improvements [Member]
Cost	$ 1,317,132	$ 1,293,258
Accumulated Depreciation	326,337	256,309
Net Carrying Value	$ 990,795	$ 1,036,949
Building Improvements [Member] | Minimum [Member]
Useful Life	5 years	5 years
Building Improvements [Member] | Maximum [Member]
Useful Life	15 years	15 years

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property and Equipment
Depreciation Expense	$ 865,262	$ 812,109
Capital expenditure	$ 1,600,000	$ 1,100,000

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Net Carrying Value	$ 110,505	$ 216,876
Patents [Member]
Cost	1,104,103	1,178,135
Accumulated Amortization	993,598	961,259
Net Carrying Value	$ 110,505	$ 216,876

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Intangible Assets
2023	$ 85,636
2024	24,869
Total Intangible Assets	$ 110,505	$ 216,876

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Amortization Expense	$ 75,558	$ 91,645
Minimum [Member] | Patents And Intellectual Property [Member]
Amortization Of Long-lived Asset On Straight Line Basis	8 years
Maximum [Member] | Patents And Intellectual Property [Member]
Amortization Of Long-lived Asset On Straight Line Basis	20 years

Income Taxes (Details)

Income Taxes (Details) - Net Deferred Tax Assets [Member] - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Net deferred tax Assets
Excess of tax over book depreciation and amortization	$ (46,001)	$ (8,330)
ROU Asset	(117,134)	(28,657)
Lease Liability	122,279	47,301
Accrued expenses	5,655	1,199
Unrealized Gain/Loss		103,106
Capitalized research expenses	1,237,122	0
Stock-based compensation	321,956	186,252
Net Operating Losses carry-forward	28,556,992	24,390,040
Research and development tax credits	769,317	606,729
Gross deferred tax assets	30,850,186	25,297,640
Valuation allowance	(30,850,186)	(25,297,640)
Net deferred tax asset	0	$ 0
Change in Valuation Allowance	$ (5,552,546)

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Summary Rate Reconciliation
Federal statutory rate	21%	21%
State income taxes, net of federal benefit	0%	0%
Permanent Differences	(0.60%)	(4.80%)
Stock based compensation	(0.30%)	(0.60%)
Federal Research & Development Credits	0.70%	0.50%
Foreign taxes	(0.10%)	1.50%
Federal Deferred Rate Decrease	0.50%	(14.40%)
Change in Valuation Allowance	(21.20%)	(3.20%)
Total	0%	0%

Income Taxes (Details 2)

Income Taxes (Details 2)	Dec. 31, 2022 USD ($)
Increase in Valuation Allowance	$ 5,552,546
United States [Member]
Net Operating Losses	35,072,965
Credit Carryforward	0
Foreign [Member]
Net Operating Losses	90,614,447
Credit Carryforward	$ 769,317

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Taxes
Net operating losses	$ 2,860	$ 2,440

Common Stock (Details)

Common Stock (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Shares Issued	24,712
Restricted Stock Units Vested	31,250
Shares Withheld for Tax	6,538
Stock Option Exercises [Member]
Common stock, share issued upon cashless exercise		277,634
Shares Issued	297,289	77,451
Restricted Stock Units Vested	377,007
Shares Withheld for Tax	79,718
February 8, 2021 | Stock Option Exercises Two [Member]
Common stock, share issued upon cashless exercise		100,000
Shares Issued		19,446
Stock Incentive Plan		2015
Price per shares		$ 5
February 8, 2021 | Stock Option Exercises [Member]
Common stock, share issued upon cashless exercise		50,000
Shares Issued		18,750
Stock Incentive Plan		2015
Price per shares		$ 3.25
February 8, 2021 | Stock Option Exercises 1 [Member]
Common stock, share issued upon cashless exercise		15,000
Shares Issued		5,769
Stock Incentive Plan		2011
Price per shares		$ 4
February 8 - February 9, 2021 | Stock Option Exercises [Member]
Common stock, share issued upon cashless exercise		85,000
Shares Issued		26,357
Stock Incentive Plan		2015
Price per shares		$ 4
January 13 - March 19, 2021 | Stock Option Exercises [Member]
Common stock, share issued upon cashless exercise		7,634
Shares Issued		948
Stock Incentive Plan		2011
Price per shares		$ 3.35
February 2, 2021 | Stock Option Exercises [Member]
Common stock, share issued upon cashless exercise		20,000
Shares Issued		6,181
Stock Incentive Plan		2011
Price per shares		$ 3.80
March 25, 2022 [Member] | Stock Option Exercises [Member]
Shares Issued	15,000
Price per shares	$ 3.01
Restricted Stock Units Vested	15,000
Shares Withheld for Tax	0
April 13, 2022 [Member] | Stock Option Exercises [Member]
Shares Issued	21,712
Price per shares	$ 2.95
Restricted Stock Units Vested	26,250
Shares Withheld for Tax	4,538
May 1, 2022 [Member] | Stock Option Exercises [Member]
Shares Issued	35,000
Price per shares	$ 2.79
Restricted Stock Units Vested	50,000
Shares Withheld for Tax	15,000
August 3, 2022 [Member] | Stock Option Exercises [Member]
Shares Issued	191,992
Price per shares	$ 1.97
Restricted Stock Units Vested	230,102
Shares Withheld for Tax	38,110
September 7, 2022 [Member] | Stock Option Exercises [Member]
Shares Issued	7,038
Price per shares	$ 1.65
Restricted Stock Units Vested	12,000
Shares Withheld for Tax	4,962
October 4, 2022 [Member] | Stock Option Exercises [Member]
Shares Issued	13,022
Price per shares	$ 1.46
Restricted Stock Units Vested	19,905
Shares Withheld for Tax	6,883
November 1, 2022 [Member] | Stock Option Exercises [Member]
Shares Issued	12,344
Price per shares	$ 1.97
Restricted Stock Units Vested	21,750
Shares Withheld for Tax	9,406
December 15, 2022 [Member] | Stock Option Exercises [Member]
Shares Issued	1,181
Price per shares	$ 1.97
Restricted Stock Units Vested	2,000
Shares Withheld for Tax	819

Common Stock (Details 1)

Common Stock (Details 1)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Restricted Stock Units Vested	31,250
Shares Issued	24,712
Shares Withheld for tax	6,538
January 20, 2021 | RSU Settlements [Member]
Restricted Stock Units Vested	5,000
Price Settled Per Share | $ / shares	$ 4.10
Shares Issued	3,000
Shares Withheld for tax	2,000
April 21, 2021 | RSU Settlements [Member]
Restricted Stock Units Vested	26,250
Price Settled Per Share | $ / shares	$ 3.44
Shares Issued	21,712
Shares Withheld for tax	4,538

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)					1 Months Ended			12 Months Ended
	May 07, 2022	Feb. 10, 2021	Nov. 10, 2020	Sep. 07, 2018	Jul. 29, 2022	May 20, 2022	Sep. 24, 2021	Dec. 31, 2022	Dec. 31, 2021
Common stock, shares issued								57,873,379	53,772,261
Issued of common stock from settlement of RSU									24,712
Issuance of common stock									77,451
Common stock price per sahres								$ 0.001
Common stock, shares authorized								100,000,000
Underwriting Agreement [Member]
Issuance of common stock		3,809,524			3,450,000			297,289
Purchase price per share		$ 4.9533			$ 1.87
Proceeds from Issuance of common stock		$ 571,428			$ 640,000
offering expenses		$ 1,890,000			$ 200,000
Equity Distribution Agreement [Member]
Common stock shares sold	3,000		754,348	2,539,606		350,829	190,600		308,609
Aggeregate share of common stock offering price			$ 25,000,000	$ 10,000,000		$ 2,500,000	$ 2,500,000
Brokerage fees	$ 9,500
Commissions and fee			$ 2,700,000	$ 9,700,000		$ 80,000	$ 700,000		$ 1,200,000

StockBased Compensation (Detail

StockBased Compensation (Details) - Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Number of warrants Outstanding beginning balance	485,000		175,000
Weighted Exercise Price
Number of warrants granted	54,000	310,000
Number of warrants exercised	0	0
Number of warrants Expired	0	0
Number of warrants outstanding ending balance	539,000	485,000
Number of Warrants Exercisable	485,000
Weighted Average Exercise Price Outstanding balance	$ 3.88		$ 2.75
Weighted Average Exercise Price Granted	3.05	$ 4.52
Weighted Exercise Price Exercised	0	0
Weighted Exercise Price Expired	0	0
Weighted Average Exercise Price ending balance	3.80	$ 3.88
Weighted Average Exercise Price exercisable	$ 3.88

StockBased Compensation (Deta_2

StockBased Compensation (Details 1)	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Warrants [Member]
Number Exercisable	485,000
Number Outstanding	539,000
Proceeds to Company if Exercised | $	$ 2,046,200
Warrant One [Member]
Weighted Average Remaining Contractual Life (Years)	1 month 24 days
Number Exercisable	125,000
Number Outstanding	125,000
Proceeds to Company if Exercised | $	$ 308,750
Exercise Price | $ / shares	$ 2.47
Warrant Two [Member]
Weighted Average Remaining Contractual Life (Years)	5 years 9 months 3 days
Number Exercisable	0
Number Outstanding	54,000
Proceeds to Company if Exercised | $	$ 164,700
Exercise Price | $ / shares	$ 3.05
Warrant Three [Member]
Weighted Average Remaining Contractual Life (Years)	3 years 2 months 1 day
Number Exercisable	50,000
Number Outstanding	50,000
Proceeds to Company if Exercised | $	$ 172,500
Exercise Price | $ / shares	$ 3.45
Warrants Four [Member]
Weighted Average Remaining Contractual Life (Years)	4 years 3 days
Number Exercisable	125,000
Number Outstanding	125,000
Proceeds to Company if Exercised | $	$ 493,750
Exercise Price | $ / shares	$ 3.95
Warrants Five [Member]
Weighted Average Remaining Contractual Life (Years)	4 years 1 month 2 days
Number Exercisable	185,000
Number Outstanding	185,000
Proceeds to Company if Exercised | $	$ 906,500
Exercise Price | $ / shares	$ 4.90

StockBased Compensation (Deta_3

StockBased Compensation (Details 2) - Option Four [Member] - USD ($)	12 Months Ended	24 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Number of options outstanding beginning balance	5,027,518	4,278,619
Granted	0	1,090,000
Exercised	0	(277,634)
Number of Expired/Cancelled	$ (42,413)	$ (63,467)
Number of option outstanding ending balance	4,985,105	5,027,518
Number of options exercisable	4,495,011
Weighted Average Exercise Price Outstanding balance	$ 3.87	$ 4
Weighted Average Exercise Price Granted	0	3.41
Weighted Average Exercise Price Exercised	0	4.19
Weighted Average Exercise Price expires/cancelled	3.43	3.64
Weighted Average Exercise Price ending balance	3.87	$ 3.87
Weighted Average Exercise Price exercisable balance	$ 3.93

StockBased Compensation (Deta_4

StockBased Compensation (Details 3) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Approved Stock options	3,342,518	3,342,518
Option expenses	$ 2,450,349
Stock Options Amendment One [Member]
Approved Stock options	292,000
Option expenses	$ 442,273
Equity Incentive Plan	2011
Stock option grant date	Jul. 23, 2015
Stock option amendment date	Jul. 14, 2021
Stock option expiration date	Jul. 23, 2025
Stock Options Amendment Two [Member]
Approved Stock options	6,367
Option expenses	$ 4,151
Equity Incentive Plan	2011
Stock option grant date	Mar. 20, 2013
Stock option amendment date	Jul. 14, 2021
Stock option expiration date	Mar. 20, 2023
Stock Options Amendment Three [Member]
Approved Stock options	8,151
Option expenses	$ 6,009
Equity Incentive Plan	2011
Stock option grant date	Sep. 02, 2013
Stock option amendment date	Jul. 14, 2021
Stock option expiration date	Sep. 02, 2023
Stock Options Amendment Four [Member]
Approved Stock options	335,000
Option expenses	$ 163,945
Equity Incentive Plan	2015
Stock option grant date	Apr. 13, 2020
Stock option amendment date	Sep. 21, 2021
Stock option expiration date	Apr. 13, 2030
Stock Options Amendment Five [Member]
Approved Stock options	89,163
Option expenses	$ 24,194
Equity Incentive Plan	2015
Stock option grant date	Jan. 23, 2018
Stock option amendment date	Sep. 21, 2021
Stock option expiration date	Jan. 23, 2028
Stock Options Amendment Six [Member]
Approved Stock options	308,066
Option expenses	$ 127,719
Equity Incentive Plan	2015
Stock option grant date	Feb. 13, 2017
Stock option amendment date	Sep. 21, 2021
Stock option expiration date	Feb. 13, 2027
Stock Options Amendment Seven [Member]
Approved Stock options	760,000
Option expenses	$ 984,511
Equity Incentive Plan	2015
Stock option grant date	Apr. 15, 2016
Stock option amendment date	Nov. 03, 2021
Stock option expiration date	Apr. 15, 2026
Stock Options Amendment Eight [Member]
Approved Stock options	15,000
Option expenses	$ 19,582
Equity Incentive Plan	2015
Stock option grant date	Jun. 23, 2016
Stock option amendment date	Nov. 03, 2021
Stock option expiration date	Jun. 23, 2026
Stock Options Amendment Nine [Member]
Approved Stock options	50,000
Option expenses	$ 32,456
Equity Incentive Plan	2015
Stock option grant date	Jan. 01, 2017
Stock option amendment date	Nov. 03, 2021
Stock option expiration date	Jan. 01, 2027
Stock Options Amendment Ten [Member]
Approved Stock options	387,934
Option expenses	$ 224,901
Equity Incentive Plan	2015
Stock option grant date	Mar. 30, 2017
Stock option amendment date	Nov. 03, 2021
Stock option expiration date	Mar. 30, 2027
Stock Options Amendment Eleven [Member]
Approved Stock options	615,837
Option expenses	$ 213,646
Equity Incentive Plan	2015
Stock option grant date	Jan. 23, 2018
Stock option amendment date	Nov. 03, 2021
Stock option expiration date	Jan. 23, 2028
Stock Options Amendment Twelve [Member]
Approved Stock options	425,000
Option expenses	$ 180,267
Equity Incentive Plan	2015
Stock option grant date	Apr. 13, 2020
Stock option amendment date	Dec. 08, 2021
Stock option expiration date	Apr. 13, 2030
Stock Options Amendment Thirteen [Member]
Approved Stock options	10,000
Option expenses	$ 5,209
Equity Incentive Plan	2015
Stock option grant date	Dec. 01, 2020
Stock option amendment date	Dec. 08, 2021
Stock option expiration date	Dec. 01, 2030
Stock Options Amendment Fourteen [Member]
Approved Stock options	40,000
Option expenses	$ 21,486
Equity Incentive Plan	2015
Stock option grant date	May 20, 2021
Stock option amendment date	Dec. 08, 2021
Stock option expiration date	May 20, 2031

StockBased Compensation (Deta_5

StockBased Compensation (Details 4)	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Option Four [Member]
Number Exercisable, shares	795,000
Number Outstanding, shares	795,000
Proceeds to Company if Exercised | $	$ 2,862,000
Exercise Price | $ / shares	$ 3.60
Weighted Average Remaining Contractual Life (years)	6 years 11 months 8 days
Options One [Member]
Number Exercisable, shares	635,000
Number Outstanding, shares	635,000
Proceeds to Company if Exercised | $	$ 2,063,750
Exercise Price | $ / shares	$ 3.25
Weighted Average Remaining Contractual Life (years)	2 years 1 month 13 days
Option Two [Member]
Number Exercisable, shares	2,717
Number Outstanding, shares	2,717
Proceeds to Company if Exercised | $	$ 9,102
Exercise Price | $ / shares	$ 3.35
Weighted Average Remaining Contractual Life (years)	8 months 1 day
Option Three [Member]
Number Exercisable, shares	532,493
Number Outstanding, shares	1,022,587
Proceeds to Company if Exercised | $	$ 3,476,796
Exercise Price | $ / shares	$ 3.40
Weighted Average Remaining Contractual Life (years)	8 years 3 months 25 days
Option Five [Member]
Number Exercisable, shares	1,682,837
Number Outstanding, shares	1,682,837
Proceeds to Company if Exercised | $	$ 6,731,348
Exercise Price | $ / shares	$ 4
Weighted Average Remaining Contractual Life (years)	3 years 9 months 3 days
Option Six [Member]
Number Exercisable, shares	11,801
Number Outstanding, shares	11,801
Proceeds to Company if Exercised | $	$ 51,334
Exercise Price | $ / shares	$ 4.35
Weighted Average Remaining Contractual Life (years)	5 months 8 days
Option Seven [Member]
Number Exercisable, shares	89,163
Number Outstanding, shares	89,163
Proceeds to Company if Exercised | $	$ 390,534
Exercise Price | $ / shares	$ 4.38
Weighted Average Remaining Contractual Life (years)	5 years 25 days
Option Eight [Member]
Number Exercisable, shares	50,000
Number Outstanding, shares	50,000
Proceeds to Company if Exercised | $	$ 240,000
Exercise Price | $ / shares	$ 4.80
Weighted Average Remaining Contractual Life (years)	4 years 3 days
Option Nine [Member]
Number Exercisable, shares	696,000
Number Outstanding, shares	696,000
Proceeds to Company if Exercised | $	$ 3,480,000
Exercise Price | $ / shares	$ 5
Weighted Average Remaining Contractual Life (years)	4 years 2 months 26 days
Total Option [Member]
Number Exercisable, shares	4,495,011
Number Outstanding, shares	4,985,105
Proceeds to Company if Exercised | $	$ 19,304,864

StockBased Compensation (Deta_6

StockBased Compensation (Details 5) - Stock Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Number of RSUs outstanding begining balance	810,750	67,500
Granted	1,892,102	789,500
Vested	(377,007)	(31,250)
Cancelled	(62,937)	(15,000)
Number of RSUs outstanding ending balance	2,262,908	810,750
Share price beginning balance	$ 3.33	$ 3.47
Share price granted	1.64	3.33
Share price vested	3.33	3.55
Cancelled net	2.88	3.3
Share price ending balance	$ 2.05	$ 3.33

StockBased Compensation (Deta_7

StockBased Compensation (Details 6) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Compensation Expense RSUs	1,892,102	789,500
RSU Expense	$ 2,755,843	$ 2,624,486
Compensation Expense Nine [Member]
Compensation Expense RSUs	450,000
Equity Incentive Plan	2015
Compensation Expense grant date	Oct. 04, 2022
Compensation Expense Vesting Period	Up to 42 Months
RSU Expense	$ 321,078
Compensation Expense Ten [Member]
Compensation Expense RSUs	3,000
Equity Incentive Plan	2015
Compensation Expense grant date	Nov. 29, 2022
Compensation Expense Vesting Period	36 Months
First Vesting date	Nov. 29, 2023
Second vesting date	Nov. 29, 2024
Third vesting date	Nov. 29, 2025
RSU Expense	$ 6,450
Compensation Expense One [Member]
Compensation Expense RSUs	8,000	5,000
Equity Incentive Plan	2015	2015
Compensation Expense grant date	Feb. 08, 2022	Jan. 01, 2021
Compensation Expense Vesting Period	24 Months
First Vesting date	Feb. 08, 2023	Jan. 01, 2021
Second vesting date	Feb. 08, 2024
RSU Expense	$ 22,640	$ 19,450
Compensation Expense Two [Member]
Compensation Expense RSUs	30,000	30,000
Equity Incentive Plan	2015	2015
Compensation Expense grant date	Mar. 01, 2022	Mar. 25, 2021
Compensation Expense Vesting Period	24 Months	24 Months
First Vesting date	Mar. 01, 2023	Mar. 25, 2022
Second vesting date	Mar. 01, 2024	Mar. 25, 2023
RSU Expense	$ 84,300	$ 107,700
Compensation Expense Three [Member]
Compensation Expense RSUs	32,000	150,000
Equity Incentive Plan	2015	2015
Compensation Expense grant date	Apr. 04, 2022	May 01, 2021
Compensation Expense Vesting Period	24 Months	36 Months
First Vesting date	Apr. 04, 2023	May 01, 2022
Second vesting date	Apr. 04, 2024	May 01, 2023
Third vesting date		May 01, 2024
RSU Expense	$ 94,400	$ 496,500
Compensation Expense Four [Member]
Compensation Expense RSUs	104,000	460,191
Equity Incentive Plan	2015	2015
Compensation Expense grant date	Apr. 04, 2022	Aug. 03, 2021
Compensation Expense Vesting Period	36 Months	24 Months
First Vesting date	Apr. 04, 2023	Aug. 03, 2022
Second vesting date	Apr. 04, 2024	Aug. 03, 2023
Third vesting date	Apr. 04, 2025
RSU Expense	$ 306,800	$ 1,523,232
Compensation Expense Five [Member]
Compensation Expense RSUs	33,000	38,000
Equity Incentive Plan	2015	2015
Compensation Expense grant date	Jun. 01, 2022	Sep. 07, 2021
Compensation Expense Vesting Period	24 Months	24 Months
First Vesting date	Jun. 01, 2023	Sep. 07, 2022
Second vesting date	Jun. 01, 2024	Sep. 07, 2023
RSU Expense	$ 80,850	$ 126,160
Compensation Expense Six [Member]
Compensation Expense RSUs	63,102	39,809
Equity Incentive Plan	2015	2015
Compensation Expense grant date	Aug. 15, 2022	Oct. 04, 2021
Compensation Expense Vesting Period	24 Months	24 Months
First Vesting date	Aug. 15, 2023	Oct. 04, 2022
Second vesting date	Aug. 15, 2024	Oct. 04, 2023
RSU Expense	$ 126,835	$ 121,019
Compensation Expense Seven [Member]
Compensation Expense RSUs	25,000	43,500
Equity Incentive Plan	2015	2015
Compensation Expense grant date	Sep. 21, 2022	Nov. 01, 2021
Compensation Expense Vesting Period	24 Months	24 Months
First Vesting date	Sep. 21, 2023	Nov. 01, 2022
Second vesting date	Sep. 21, 2024	Nov. 01, 2023
RSU Expense	$ 42,250	$ 152,685
Compensation Expense Eight [Member]
Compensation Expense RSUs	1,144,000	23,000
Equity Incentive Plan	2015	2015
Compensation Expense grant date	Oct. 04, 2022	Dec. 15, 2021
Compensation Expense Vesting Period	36 Months	24 Months
First Vesting date	Oct. 04, 2023	Dec. 15, 2022
Second vesting date	Oct. 04, 2024	Dec. 15, 2023
Third vesting date	Oct. 04, 2025
RSU Expense	$ 1,670,240	$ 77,740

StockBased Compensation (Deta_8

StockBased Compensation (Details 7) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity Incentive RSU	377,007	31,250
Incentive RSU Issued	297,289	24,712
RSUs Held for Taxes	$ 79,718	$ 6,538
Equity Incentive Plan One [Member]
Incentive Plan	2015	2015
Equity Incentive RSU	15,000	5,000
Incentive Vest Date	Mar. 25, 2022	Jan. 01, 2021
Incentive RSU Issued	15,000	3,000
RSUs Held for Taxes	$ 0	$ 2,000
Equity Incentive Plan Two [Member]
Incentive Plan	2015	2015
Equity Incentive RSU	26,250	26,250
Incentive Vest Date	Apr. 13, 2022	Apr. 13, 2021
Incentive RSU Issued	21,712	21,712
RSUs Held for Taxes	$ 4,538	$ 4,538
Equity Incentive Plan Three [Member]
Incentive Plan	2015
Equity Incentive RSU	50,000
Incentive Vest Date	May 01, 2022
Incentive RSU Issued	35,000
RSUs Held for Taxes	$ 15,000
Equity Incentive Plan Four [Member]
Incentive Plan	2015
Equity Incentive RSU	230,102
Incentive Vest Date	Aug. 03, 2022
Incentive RSU Issued	191,992
RSUs Held for Taxes	$ 38,110
Equity Incentive Plan Five [Member]
Incentive Plan	2015
Equity Incentive RSU	12,000
Incentive Vest Date	Sep. 07, 2022
Incentive RSU Issued	7,038
RSUs Held for Taxes	$ 4,962
Equity Incentive Plan Six [Member]
Incentive Plan	2015
Equity Incentive RSU	19,905
Incentive Vest Date	Oct. 04, 2022
Incentive RSU Issued	13,022
RSUs Held for Taxes	$ 6,883
Equity Incentive Plan Seven [Member]
Incentive Plan	2015
Equity Incentive RSU	21,750
Incentive Vest Date	Nov. 01, 2022
Incentive RSU Issued	12,344
RSUs Held for Taxes	$ 9,406
Equity Incentive Plan Eight [Member]
Incentive Plan	2015
Equity Incentive RSU	2,000
Incentive Vest Date	Dec. 15, 2022
Incentive RSU Issued	1,181
RSUs Held for Taxes	$ 819

StockBased Compensation (Deta_9

StockBased Compensation (Details 8) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
RSU Cancelled	62,937	15,000
Incentive RSU	62,937	15,000
Equity Incentive Plan One [Member]
RSU Cancelled	33,000	15,000
Incentive Plan	2015	2015
Incentive RSU	33,000	15,000
Cancellation Date	May 31, 2022
Vest date		Dec. 31, 2020
Equity Incentive Plan Two [Member]
RSU Cancelled	1,365
Incentive Plan	2015	2015
Incentive RSU	1,365
Cancellation Date	Aug. 18, 2022
Equity Incentive Plan Three [Member]
RSU Cancelled	17,572
Incentive Plan	2015
Incentive RSU	17,572
Cancellation Date	Nov. 18, 2022
Equity Incentive Plan Four [Member]
RSU Cancelled	11,000
Incentive Plan	2015
Incentive RSU	11,000
Cancellation Date	Nov. 21, 2022

StockBased Compensation (Det_10

StockBased Compensation (Details 9)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Option Four [Member]
Number of stock Outstanding balance	63,102
Share price | $ / shares	$ 2.01
Weighted average remaining contractual life (Years)	1 year 29 days
Options One [Member]
Number of stock Outstanding balance	450,000
Share price | $ / shares	$ 0.69
Weighted average remaining contractual life (Years)	3 years 3 months 3 days
Option Two [Member]
Number of stock Outstanding balance	1,133,000
Share price | $ / shares	$ 1.46
Weighted average remaining contractual life (Years)	1 year 9 months 3 days
Option Three [Member]
Number of stock Outstanding balance	25,000
Share price | $ / shares	$ 1.69
Weighted average remaining contractual life (Years)	1 year 2 months 19 days
Option Five [Member]
Number of stock Outstanding balance	3,000
Share price | $ / shares	$ 2.15
Weighted average remaining contractual life (Years)	1 year 10 months 28 days
Option Six [Member]
Number of stock Outstanding balance	33,000
Share price | $ / shares	$ 2.45
Weighted average remaining contractual life (Years)	11 months 1 day
Option Seven [Member]
Number of stock Outstanding balance	30,000
Share price | $ / shares	$ 2.81
Weighted average remaining contractual life (Years)	8 months 1 day
Option Eight [Member]
Number of stock Outstanding balance	8,000
Share price | $ / shares	$ 2.83
Weighted average remaining contractual life (Years)	7 months 9 days
Option Nine [Member]
Number of stock Outstanding balance	136,000
Share price | $ / shares	$ 2.95
Weighted average remaining contractual life (Years)	11 months 19 days
Total Option [Member]
Number of stock Outstanding balance	2,262,908
Option Ten [Member]
Number of stock Outstanding balance	19,904
Share price | $ / shares	$ 3.04
Weighted average remaining contractual life (Years)	4 months 17 days
Option Eleven [Member]
Number of stock Outstanding balance	311,152
Share price | $ / shares	$ 3.31
Weighted average remaining contractual life (Years)	7 months 2 days
Option Twelve [Member]
Number of stock Outstanding balance	12,000
Share price | $ / shares	$ 3.32
Weighted average remaining contractual life (Years)	8 months 4 days
Option Fourteen [Member]
Number of stock Outstanding balance	21,750
Share price | $ / shares	$ 3.51
Weighted average remaining contractual life (Years)	5 months 1 day
Option Fiveteen [Member]
Number of stock Outstanding balance	15,000
Share price | $ / shares	$ 3.59
Weighted average remaining contractual life (Years)	2 months 23 days
Option Thirteen [Member]
Number of stock Outstanding balance	2,000
Share price | $ / shares	$ 3.38
Weighted average remaining contractual life (Years)	5 months 23 days

StockBased Compensation (Det_11

StockBased Compensation (Details Narrative) - USD ($)						1 Months Ended					9 Months Ended	12 Months Ended
	Apr. 04, 2022	Oct. 04, 2021	Sep. 07, 2021	Aug. 03, 2021	Apr. 13, 2020	Nov. 29, 2022	Nov. 18, 2022	Aug. 18, 2022	May 20, 2021	May 27, 2019	Sep. 30, 2019	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Jun. 15, 2018	Mar. 27, 2018	Jun. 13, 2017	Aug. 05, 2016
Common stock available	1,750,000
Share aggregate maximum	7,750,000
Option Granted				2,515	5,000		32,383	2,515
Stock options approved amount												3,342,518	3,342,518
Common stock available for issuance												$ 6,736,444	$ 23,219,644
Stock price									$ 3.50
Volatility									76.16%
Risk free rate									0.58%
Stock-based compensation expense												$ 0	2,450,349
Restricted Stock Units [Member] | One
Vesting aggregate												198,275
Aggregrate aggregate												424,875
share price												$ 5
Granted aggregate						3,000
Granted RSU		39,809		460,191
Description of vesting shall		These RSUs vest over two years with 19,905 units vesting on October 4, 2022, and 19,904 units vesting on October 4, 2023, subject to continued service and will result in total compensation expense of $121,019		The RSUs eligible for vesting shall vest over two years with up to 230,102 units vesting on August 3, 2022, and up to 230,089 units vesting on August 3, 2023 and will result in total compensation expense of $1,523,232
Stock-based compensation expense												$ 1,903,054	898,910
unrecognized compensation cost												2,214,593
Option [Member]
Stock-based compensation expense												1,127,502	1,069,605
Option [Member] | 2015 Equity Incentive Plan [Member]
Shares vesting		36,680
Fair value of options		$ 128,003	$ 98,322	$ 1,811,216								$ 287,363
Common stock shares issuable upon exercise of stock option			25,000	463,328
Exercise price		$ 3.40	$ 3.40	$ 3.40								$ 3.87
Maturity Term			5 years 6 months	5 years 6 months								5 years 2 months 19 days
Common stock available for issuance										$ 1,750,000		$ 750,000
Stock price		$ 3.04	$ 3.32	$ 3.31
Volatility		68.80%	68.98%	69.13%
Risk free rate		1.49%	1.38%	1.19%
Stock option purchase		36,680	25,000	463,312
Vesting term		10 years	10 years									9 months 3 days
Common stock shares reserved for future issuance		73,360	50,000	926,640								417,318			750,000	1,000,000		750,000
Option [Member] | 2015 Equity Incentive Plan [Member] | Maximum [Member]
Common stock shares reserved for future issuance														6,000,000	3,250,000	4,250,000	2,500,000	1,750,000
Warrants [Member]
Stock-based compensation expense												$ 84,102	$ 701,781
Intrinsic value												$ 0
Vesting term												1 year 3 months 3 days
Compensation cost related to non-vested warrants												$ 35,812
April 4, 2022 [Member] | Warrants [Member]
Exercise price												$ 3.05
Maturity Term												3 years 6 months
Stock price												$ 2.95
Warrants exercise price												$ 3.05
Volatility												71.07%
Risk free rate												2.53%
February 1, 2021 [Member] | Warrants [Member]
Exercise price												$ 4.90
Maturity Term													3 years 6 months
Stock price													$ 4.80
Warrants exercise price												$ 4.90
Volatility													75.03%
Risk free rate													0.59%
Stock option purchase													185,000
Expire description												This warrant shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service and expire on April 4, 2028 and April 4, 2029, respectively, with an exercise price of $3.05 per share	These warrants vest on January 1, 2022 (subject to continued employment through such date) and expire on January 1, 2027, with an exercise price of $3.95 per share.
Warrant expenses													$ 459,352
January 01, 2021 [Member] | Warrants [Member]
Exercise price												$ 3.95
Maturity Term												3 years 6 months
Stock price												$ 3.80
Volatility rate												74.53%
Risk free rate												0.50%
Stock option purchase												54,000	125,000
Warrant expenses												$ 80,901	$ 242,877
Fair market value of options													$ 73,641
April 13,2020 [Member] | Restricted Stock Units [Member]
Stock compensation expenses											$ 0
On 20, May 2021 [Member] | Option [Member]
Exercise price									$ 3.60			$ 3.60
Maturity Term									3 years 6 months
Stock options purchase shares of common stock													40,000

Commitments and Contingencies_2

Commitments and Contingencies (Details) - Finance Lease Obligations [Member]	Dec. 31, 2022 USD ($)
2023	$ 57,726
2024	57,725
2025	57,725
2026	57,726
2027	57,726
Greater than 5 years	252,534
Total	541,162
Less: Amount representing interest	(59,016)
Present value of minimum lease payments	$ 482,146

Commitments and Contingencies_3

Commitments and Contingencies (Details 1) - Operating Lease Right of Use Obligations [Member]	Dec. 31, 2022 USD ($)
2023	$ 264,799
2024	164,225
2025	120,209
2026	94,600
2027	25,800
Total Operating Lease Obligations	669,633
Less: Amount representing interest	(24,379)
Present value of minimum lease payments	$ 645,254

Commitments and Contingencies_4

Commitments and Contingencies (Details 2)	Dec. 31, 2022 USD ($)
Commitments and Contingencies
2023	$ 27,069
2024 - 2027	0
Total Operating Lease Liabilities	$ 27,069

Commitments and Contingencies_5

Commitments and Contingencies (Details 3) - Grants Repayable [Member]	Dec. 31, 2022 USD ($)
2023	$ 49,283
2024	26,541
2025	34,581
2026	42,026
2027	45,978
Greater than 5 years	263,893
Total Grants Repayable	$ 462,302

Commitments and Contingencies_6

Commitments and Contingencies (Details 4)	Dec. 31, 2022 USD ($)
Commitments and Contingencies
2023	$ 1,268,528
2024	1,138,227
2025	704,312
2026	480,358
2027	281,602
Greater than 5 years	446,799
Total	4,319,826
Less: Amount representing interest	(473,886)
Total Long-Term Debt	$ 3,845,940

Commitments and Contingencies_7

Commitments and Contingencies (Details 5)	Dec. 31, 2022 USD ($)
Commitments and Contingencies
2022	$ 798,032
2024 - 2027	81,773
Total Collaborative Agreement Obligations	$ 879,805

Commitments and Contingencies_8

Commitments and Contingencies (Details 6) - Stock Option	12 Months Ended
	Dec. 31, 2022 USD ($)
Outstanding Award 1
Outstanding award	$ 969,593
Amortised of outstanding award 2022	580,411
Amortised of outstanding award 2021	389,182
Un-amortised of outstanding award 2023	0
Outstanding Award 2
Outstanding award	630,863
Amortised of outstanding award 2022	450,090
Amortised of outstanding award 2021	180,773
Un-amortised of outstanding award 2023	$ 270,550

Commitments and Contingencies_9

Commitments and Contingencies (Details 7) - Restricted stock option	12 Months Ended
	Dec. 31, 2022 USD ($)
Outstanding Award 1
Outstanding award	$ 822,149
Amortised of outstanding award 2022	493,207
Amortised of outstanding award 2021	328,942
Un-amortised of outstanding award 2023	0
Outstanding Award 2
Outstanding award	530,930
Amortised of outstanding award 2022	379,191
Amortised of outstanding award 2021	151,739
Un-amortised of outstanding award 2023	$ 228,491

Commitments and Contingencie_10

Commitments and Contingencies (Details 8)	12 Months Ended
	Dec. 31, 2022 USD ($)
Amortised of outstanding award 2022	$ 245,861
Un-amortised of outstanding award	$ 1,408,319
Restricted stock option | Outstanding Award 1
Vesting period	2023
Amortised of outstanding award 2022	$ 134,087
Un-amortised of outstanding award	417,327
Restricted stock option | Outstanding Award 2
Amortised of outstanding award 2022	65,088
Un-amortised of outstanding award	$ 470,244
Outstanding award	2024
Restricted stock option | Outstanding Award 3
Amortised of outstanding award 2022	$ 46,686
Un-amortised of outstanding award	$ 520,748
Outstanding award	2025

Commitments and Contingencie_11

Commitments and Contingencies (Details Narrative)		12 Months Ended
	Nov. 03, 2020	Dec. 31, 2022 USD ($) shares	Dec. 31, 2022 EUR (€) shares	Dec. 31, 2021 USD ($)	Dec. 31, 2022 EUR (€)
Grant Repyable		$ 462,302
Long-term debt payable		3,845,940
Payments For Future Research And Collobration		$ 879,805
RoyalityOnRevenuePercentange		6%	6%
Aggerate Amount Payable, Description	under the agreement will be completed by the end of the third quarter 2023 at a total cost to the Company of up to $4.2 million
Amount payable		$ 264,692
Payable By Company For Services Rendered		$ 3,435,165
Restricted stock unit | shares		1,144,000	1,144,000
Accrued compensation expense		$ 905,856
Unrecognized compensation expense		270,550
Stock-based compensation expense		0		$ 2,450,349
Compensation		737,137
Other income		1,181,603		$ 1,343,298
Performance Based Award [Member] | Vest In 2023 [Member]
Unrecognized compensation expense		228,491
RSu Vested		530,930
Stock-based compensation expense		822,149
Performance Based Award [Member] | Vest In 2024 [Member]
Unrecognized compensation expense		1,408,319
RSu Vested		134,087
RSu Vested in 2024		65,088
RSu Vested in 2025		46,686
Stock-based compensation expense		245,861
Finance Lease Obligations [Member]
Lease Payable		541,162
Operating Lease Right of Use Obligations [Member]
Operating Lease Right-of-use Assets		619,392
Operating Lease Liabilities		$ 645,254
Weighted Average Discount Rate		2.38%			2.38%
Payment Of Lease Liabilities		$ 245,354
Operating Lease Expense		267,434
Short Term Lease Costs		76,955
Managing Director's Agreement [Member]
Amount payable		210
Royalty Payment		$ 118,055
Royality		6%	6%
Stock Incentive Plan [Member]
Stock Option Expenses		$ 969,593
Restricted Stock		500,000
Total Of Stock Option		$ 1,000,000
In 2018 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | Namur Innovation and Growth [Member]
Loan Agreement Term		4 years	4 years
Repayment Of Long-term Loan Amount | €			€ 500,000
Fixed Interest Rate		4%			4%
Maturity Date		June 2022	June 2022
Total Long-term Debt		$ 0
February 5, 2022 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | First Insurance Funding [Member]
Loan Agreement Term		9 months	9 months
Repayment Of Long-term Loan Amount		$ 620,549
Fixed Interest Rate		3.57%			3.57%
Maturity Date		November 2022	November 2022
Principal Balance Payable		$ 0
On September 16, 2020 [Member] | Bioinformatic Analytics Of Cell Free DNA [Member]
Repayment Of Long-term Loan Amount | €			€ 54,879
Total Long-term Debt		100,236
Additional Cost Of Company		39,000
Collaborative Obligations Amount Due		23,018
August Ten Two Thousand Twenty Two [Member] | Univercity Of Texas MD [Member]
Additional Cost Of Company		346,787
Collaborative Obligations Amount Due		346,787
In 2019 [Member] | Collaborative Arrangement, Co-promotion [Member]
Collaborative Obligations Amount Due		$ 0
Lease Agreement Expire Period		5	5
Collaborative Obligations Amount		$ 400,000
In 2018 [Member] | BNP Paribas leasing solutions [Member] | Finance Lease Obligations [Member]
Amount payable		$ 0
Purchase Price For The Property | €					€ 25,000
Maturity Date		January 2022	January 2022
Implicit Interest		1.35%			1.35%
Leased Equipment Amortized Term		5 years	5 years
Walloon Region Government [Member] | In 2020 [Member]
RoyalityOnRevenuePercentange		2.89%	2.89%
Repayment Of Grants | €					€ 148,500
Terms Of Agreement Description		it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received	it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received
Amount Repayable		$ 97,799
Grant Receivable | €					495,000
Grant Repaid By Installments		over 10 years	over 10 years
Walloon Region Government [Member] | In 2020 [Member] | Colorectal Cancer Research Agreement [Member]
RoyalityOnRevenuePercentange		4.34%	4.34%
Repayment Of Grants | €					278,830
Terms Of Agreement Description		it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received	it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received
Amount Repayable		$ 230,392
Grant Receivable | €					929,433
Grant Repaid By Installments		over 15 years	over 15 years
Walloon Region Government [Member] | In 2018 [Member] | Colorectal Cancer Research Agreement [Member]
RoyalityOnRevenuePercentange		3.53%	3.53%
Repayment Of Grants | €					181,500
Terms Of Agreement Description		it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received	it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received
Amount Repayable		$ 107,280
Grant Receivable | €					605,000
Grant Repaid By Installments		over 12 years	over 12 years
Walloon Region Government [Member] | In 2010 [Member]
RoyalityOnRevenuePercentange		6%	6%
Repayment Of Grants | €					314,406
Other income		$ 733,614
Terms Of Agreement Description		it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is twice the amount of funding received	it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is twice the amount of funding received
Amount Repayable		$ 26,831
Grant Receivable | €					€ 1,048,020
Namur Invest [Member] | In 2016 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Loan Agreement Term		7 years	7 years
Repayment Of Long-term Loan Amount | €			€ 440,000
Fixed Interest Rate		4.85%			4.85%
Maturity Date		December 2023	December 2023
Total Long-term Debt		$ 82,659
Namur Invest [Member] | In 2019 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Loan Agreement Term		4 years	4 years
Repayment Of Long-term Loan Amount | €			€ 500,000
Fixed Interest Rate		4.80%			4.80%
Maturity Date		September 2024	September 2024
Total Long-term Debt		$ 279,548
Namur Invest [Member] | In 2020 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Loan Agreement Term		10 years	10 years
Repayment Of Long-term Loan Amount | €			€ 830,000
Fixed Interest Rate		4%			4%
Maturity Date		March 2031	March 2031
Principal Balance Payable		$ 759,419
Agreement Under Amount | €			€ 707,599
ING [Member] | In 2016 [Member] | Long-term Debt [Member]
Maturity Date		May 2031	May 2031
Fixed Interest Rate On Lease		2.62%			2.62%
Lease Payable		$ 482,146
ING [Member] | In 2016 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Loan Agreement Term		15 years	15 years
Repayment Of Long-term Loan Amount | €			€ 270,000
Fixed Interest Rate		2.62%			2.62%
Maturity Date		December 2031	December 2031
Principal Balance Payable		$ 188,806
SOFINEX [Member] | In 2017 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Loan Agreement Term		7 years	7 years
Repayment Of Long-term Loan Amount | €			€ 1,000,000
Fixed Interest Rate		4.50%			4.50%
Maturity Date		September 2024	September 2024
Total Long-term Debt		$ 482,954
SOFINEX [Member] | November 23, 2021 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Loan Agreement Term		3 years 5 months 30 days	3 years 5 months 30 days
Repayment Of Long-term Loan Amount | €			€ 450,000
Fixed Interest Rate		5%			5%
Maturity Date		June 2025	June 2025
Principal Balance Payable		$ 442,708
Agreement Under Amount | €			€ 450,000
University of Taiwan [Member] | In 2018 [Member] | Clinical Study Research Agreement [Member]
Collaborative Obligations Amount Due		510,000
Collaborative Obligations Amount		$ 2,550
Lease Agreement Expire Period		3 years	3 years
Namur [Member] | August 16, 2022 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Loan Agreement Term		4 years	4 years
Repayment Of Long-term Loan Amount | €			€ 1,000,000
Fixed Interest Rate		6%			6%
Maturity Date		July 2026	July 2026
Principal Balance Payable		$ 1,073,231
Agreement Under Amount | €			€ 1,000,000
Namur [Member] | November 18, 2022 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Loan Agreement Term		4 years	4 years
Repayment Of Long-term Loan Amount | €			€ 500,000
Fixed Interest Rate		5.45%			5.45%
Maturity Date		December 2027	December 2027
Principal Balance Payable		$ 536,615
Agreement Under Amount | €			€ 500,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)			1 Months Ended		12 Months Ended
	Jan. 12, 2023	Jan. 05, 2023	Feb. 17, 2023	Jan. 19, 2023	Dec. 31, 2022	Dec. 31, 2021	Mar. 01, 2023	Feb. 08, 2023
Common stock, shares issued					57,873,379	53,772,261
Net proceeds					$ 306,392	$ 90,035
2015 Equity Incentive Plan [Member] | Option [Member]
RSUs, vested							15,000	4,000
Common stock, shares issued							9,609	2,369
Common stock, shares withheld for taxes							5,391	1,631
Capital Raise [Member]
Shares issued			4,945,000
Share price			$ 1.6275
Proceed from sale of common stock			$ 8,000,000
RSU Vesting [Member]
RSUs, vested	424,875
Description of rsu vesting	3-year time based vesting schedule, vesting in three equal installments on each of October 4, 2023, October 4, 2024 and October 4, 2025
Common Stock Issuances And Repurchases [Member]
Net proceeds				$ 656,000
Sale of common stock				$ 279,703
Common stock, share purchase		13,264
Common stock, per share		$ 2.39
Total cost of the company		$ 31,772